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ABSTRACT OF THE DISSERTATION
Therapeutic Modalities Targeting Neuroinflammation After Neonatal Hypoxia-Ischemia
by
Nancy Fathali
Doctor of Philosophy, Graduate Program in Anatomy
Loma Linda University, June 2010
Dr. John H. Zhang, Chairperson
Hypoxia-ischemia (HI) occurs in 1-6/1000 live full-term births (Shankaran,
2009). Of those affected, 15-20% will die in the postnatal period, and 25% of survivors
will be left with long-term neurological disabilities (Gunn, 2000; Vannucci, 1997;
Fatemi, 2009). It has become increasingly clear that peripheral immune cells infiltrate the
brain parenchyma as part of the physiological response to tissue damage after HI injury.
The interplay between infiltrating immune cells and brain resident cells during the
inflammatory response is however dynamic and complex; in that neuro-immune
crosstalk, by way of specific molecular mediators, is responsible for both
neurodestructive as well as neuroprotective outcomes. Herein, we tested the hypothesis
that COX-2 mediates mechanisms of brain injury and that G-CSF exerts structural and
functional protection after neonatal HI.
To mimic the clinical features of HI brain injury, neonatal rat pups were subjected
to unilateral carotid artery ligation followed by 2 hours of hypoxia (8% O2 at 37°C). We
used a gain and loss of function approach (pharmacological activation or inhibition,
respectively) for COX-2, a neutralizing antibody for lL-15, and a gene silencer for
natural killer cells in both splenectomized and non-splenectomized rats to verify the role
of COX-2 in splenic immune cell responses following HI. We found that elevations in
Xlll
COX-2 expression by immune cells promoted IL-15 expression in astrocytes and
infiltration of infiammatory cells; additionally, down-regulated the pro-survival protein,
PI3K, resulting in caspase-3 mediated neuronal death. Additionally, we investigated the
efficacy of G-CSF on long-term Hl-induced morphological and functional outcomes
using two different dosing regimens; and found the neurotrophic factor to significantly
improve behavioral and neuropathological recovery.
These results provide insight into the mechanistic basis of mflammation and
indentify key components of the neuroinflammatory response after HI. Thus, we propose
that COX-2 inhibition or G-CSF administration during the acute phase of injury are novel
therapeutic modalities that target detrimental and beneficial mechanisms of
neuroinflammation, respectively, and may offer a safe and effective option with long-
term benefits for the Hl-injured infant.
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CHAPTER ONE
THE EVOLVING LANDSCAPE OF NEUROINFLAMMATION AFTER NEONATAL
HYPOXIA-ISCHEMIA
Nancy Fathali^ Nikan H. Khatibi^, Robert P. Ostrowski^, and John H. Zhang^'^'"^
Departments of 'Pathology and Human Anatomy, ̂Anesthesiology, ̂Physiology, and
''Neurosurgery, Loma Linda University, Loma Linda, CA, USA
Published: Acta Neurochirurgica Supplement, In Press
Abstract
Hypoxic-ischemic brain injury remains a leading cause of mortality and morbidity
in neonates. The inflammatory response, which is characterized, in part, by activation of
local immune cells, has been implicated as a core component for the progression of
damage to the immature brain following hypoxia-ischemia (HI). However, moxmting
evidence implicates circulating immxme cells recruited to the site of damage, as
orchestrators of neuron-glial interactions and perpetuators of secondary brain injury. This
suggests that re-directing our attention from the local inflammatory response toward the
molecular mediators believed to link brain-immune cell interactions may be a more
effective approach to mitigating the inflammatory sequelae of perinatal HI. In this
review, we focus our attention on cyclooxygenase-2 (COX-2), a mediator by which
peripheral immune cells may modulate signaling pathways in the brain that lead to a
worsened outcome. Additionally, we present an overview of emerging therapeutic
modalities that target mechanisms of neuroinflammation in the hypoxic-ischemic
neonate.
Introduction
Hypoxia-ischemia (HI) occurs in one to six per 1000 live full-term births (63). Of
those affected, 15-20% will die in the postnatal period, and 25% of survivors will be left
with long-term neurological disabilities (24,32,70). Intrauterine asphyxia is the
underlying mechanism of hypoxic injury and is a consequence of circulatory problems
including clotting of placental arteries and placental abruption (50). HI in the neonate is a
manifestation of systemic hypoxia combined with reduced cardiac output (48).
Studies have shown that the pathophysiology of brain injury secondary to HI
consists of a biphasic profile (Figure 1). The initial phase of HI is characterized by brain
acidosis and the depletion of high-energy phosphorylated compounds, such as adenosine
triphosphate and phosphocreatine (12,33,63). This primary energy failure leads to the loss
of membrane ionic homeostasis, depolarization of the cell, osmotic dysregulation, and
inhibition of protein synthesis, fiorther leading to necrosis (39,44). The secondary
processes evolve over days after the brain insult, and are also characterized by a depletion
of high-energy phosphorylated compounds however without tissue acidosis. Although the
pathogenesis of secondary brain injury involves multiple pathophysiologic processes,
accumulating evidence implicates the inflammatory response as a core component of
damage (3,25,26).
Neuroinflammation includes initial release of pro-inflammatory mediators by
injured or dying cells, activation of microglia and astrocytes, and leukocyte infiltration. It
is the synergistic actions of these events that potentiate brain damage and lead to
neurological dysfunction (56). However, experimental studies thus far have focused
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Figure 1. Pathophysiology of a Hypoxic-Ischemic Event. Decrease in cerebral blood
flow results in a decrease of high-energy phosphate reserves (i.e., adenosine triphosphate;
phosphocreatine) and a huild-up of lactic acid. Loss of memhrane ionic homeostasis leads
to intracellular accumulation of sodixim (Na"^), calcium (Ca^"^, and water (edema);
thereby depolarizing the cell and releasing glutamate (triangle) and potassium (K^) into
the extracellular space. Intracellular calcium ion accumulation leads to enzyme induction
(i.e., Upases; proteases; endonueleases) and free fatty acid elevation, which undergo
peroxidation. The result is the accumulation and/or release of inflammatory mediators
(i.e., cyclooxygenase-2) \yhich can lead to apoptosis, glial activation, and peripheral
immune cell infiltration.
pharaiacotherapies proven clinically viable for the treatment of HI brain damage. In fact,
increasing evidence suggests identifying molecular mediators responsible for
orchestrating brain-immune cell interactions as a more promising approach (18,20,49).
This review will provide a brief overview of the current understanding of the local
and peripheral inflammatory response involved in neonatal HI, and the role of
cyclooxygenase-2 (COX-2) in brain-immune cell interactions and the progression of
neuroinflammation.
Changing Landscape of Neuroinflammation
The immune response in the brain is highly complex and involves the
participation of several different resident cells (Figure 2). Microglia, astrocytes, and
neurons directly react and contribute to neuroinflammation in the Hl-injured neonate. The
role of each of these cell types in propagating the local inflammatory response is
important in understanding the dynamic microenvironment.
Microglia
Microglia cells serve as specialized sensors for brain tissue damage. In response
to ischemia, microglia morphologically change from a resting ramified phenotype to a
motile activated amoeboid cell able to migrate to necrotic areas to remove cellular debris
(43,44). However, in the process, these activated cells contribute to secondary brain
injury by releasing a variety of pro-inflammatory mediators including cytokines, reactive
oxygen species, complement factors, free radical species and nitric oxide, which
contribute to cell death, ultimately creating a vicious perpetuating cycle (24).
Mounting evidence suggests that infiltrating peripheral immune cells may be
necessary for the activation of microglia, thereby exacerbating neurodegeneration after
ischemia. In an in vitro study, microglia when co-cultured with T-cells, become activated
thereby releasing an inflammatory cytokine (14). In an in vivo study, removal of a
population of infiltrating macrophages, neutrophils, B cells, and T cells by splenectomy
appeared to reduce microglia activation and dramatically reduce brain damage (2).
Systemic inhibition of monocyte/macrophage or neutrophil populations hais also shown to
reduce cerebral infarct volume after ischemic injury (16,17,78). However, the exact
mechanism by which peripheral immune cells activate and/or propagate the local
inflammatory response and enhance neuronal death remains to be determined.
Astrocytes
Astrocytes which are the predominant glial cell type in the central nervous system
(CNS), have been shown to produce inflammatory mediators in a variety of brain injures
including HI (61,62). Inflammatory cytokines have been associated with neonatal HI
brain damage, and later development of cerebral palsy (19,24). Specifically, elevated
levels of interleukin (IL)-6 in cerebrospinal fluid of asphyxiated newboms have been
correlated with an increased degree of brain damage and poor neurological outcome (58).
Additionally, more recent evidence has implicated IL-15 as playing a leading role in
neuroinfiammation in the injured immature rat brain (51). Importantly, astrocytes are the
main source of both IL-6 and IL-15 in CNS injury and inflammation (24,29).
Astrocytes may also influence the local inflammatory response through their
communicative partnership with neighboring cells (31). Under pathological conditions,
astrocytes play a critical role in the activation of microglia (55,67), and by-products of
reactive astrocytes such as tumor necrosis factor-alpha (TNF-a) and IL-6 arc associated
with ncuronal demise after HI (72). On the other hand, astrocytes are also a source of
trophic factors, such as granulocyte-colony stimulating factor (G-CSF) (22), and are
responsible for regulating neurotransmitter and ion concentrations, removing debris, and
maintaining an optimal environment for ncuronal function (5). Impairment of astrocyte
function during HI is thought to influence neuron viability (72). Therefore, it is important
to identify key molecular mediators responsible for initiating astrocyte signaling
pathways involved in worsening brain injury, without eliminating the protective function
of these cells.
Neurons
Once thought to be passive bystanders in neuroinflammation, neurons are now
known to be playing more of an active role. As such, neurons can be a source of
inflammatory mediators including complement, COX-2 and cytokines after HI (25,68).
Neurons can express COX-2 at low levels under normal conditions; however, under
pathological conditions, COX-2 is upregulated in response to mitogens, inflammatory
mediators, and hormones (38). Induction of COX-2 expression in neurons is also driven
by physiological synaptic activity (73) and acute paradigms of excitoxicity (1), whereby
promoting local inflammatory reactions and injury to themselves (23,53,54). Moreover,
neurons contribute to the production of pro-inflammatory mediators that can alter
vascular permeability and regional blood flow, and enhance chemotactic activity and
thereby promote leukocyte migration (3).
Once peripheral leukoeytes and monocytes enter the brain parenchyma their
actions appear to be multifaceted (77). Certain immrme cell subpopulations may directly
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elicit neuronal death via contact-dependent mechanisms (28) or release molecular
mediators that activate resident cells, thus promoting further brain injury (4,11). In line
with this concept, recent studies have shown that T-lymphocyte-deficient mice
demonstrate attenuated brain injury and neurological deficits after experimental stroke
(37,76). To make matters more complex, regulatory T-lymphocytes have been shown to
have a protective role in the brain after stroke (45). Immune cells have been also
implicated in the generation of new neurons and improvement of spatial learning and
memory performance in neurodegenerative disease (7,79,80).
Figure 2. Neuroinflammatory Cascade After Brain Injury. Downstream cyclooxygenase-
2 (COX-2) effectors from infiltrating peripheral immune cells activate astrocytes and
microglia, which in turn, release cytokines, chemokines, reactive oxygen and nitrogen
species (ROS and RNS, respectively) and complement factors. These inflammatory
mediators can further activate resident brain cells, thereby amplifying neuroinflammatory
signals and neuronal cell death. Excessive exposure to inflammatory mediators
compromises astrocyte functions leading to downregulation of glutamate transporters,
impaired glutamate re-uptake, elevated glutamate release, and decreased neurotrophic
factor (i.e., granulocyte-colony stimulating factor [G-CSF]) release, all of which can lead
to neuronal cell death. Neuronal release of cytokines, complement factors, and COX-2
can lead to autocrine or paracrine-mediated neuronal death.
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Neuro-Glial Interactions
Astrocytes are viewed as an active participant in synaptic transmission and
processing of information - a departure from the old dogma in which astrocytes were
identified as merely physical supporters for neighboring neurons (5). Moreover, opening
of gap-junctional communication channels links dying astroc3des in the ischemic core
with penumbral cells (46). Therefore, astrocytes might compromise juxtaposed cells
found in salvageable tissue that otherwise may have survived.
Studies have suggested that inflammatory mediators might be the driving force
for altering astrocyte fimction and thereby impacting neuron-glial signaling. For example,
astrocytes undergo IL-lb-induced elevations in intracellular calcium which may enhance
glia-to-neuron signaling, leading to a reduction in neuron survival (9). Pro-inflammatory
cjdokines may also be responsible for impairing astrocyte energy metabolism thereby
jeopardizing neuronal vulnerability (5). Thus it is reasonable to conceptualize that
targeting cytokines may lead to a profound modulation of astrocyte function and improve
neuronal survivability in this mechanism.
Central Role of COX-2
Cyclooxygenase is a rate limiting enzyme responsible for catalyzing the synthesis
of prostaglandins from arachidonic acid (66). Cyclooxygenase possesses two catalytic
sites: a COX active site responsible for the conversion of arachidonic acid into the
endoperoxide, PGG2; and a peroxidase active site responsible for the rapid conversion of
PGG2 into another endoperoxide, PGH2 (10). PGH2 is further processed to form
prostaglandins, prostacyclin, and thromboxane A2. To date, two COX isoforms have been
identified. COX-1 is constitutively expressed in the brain and its by-products are thought
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to contribute to normal physiological function (74). COX-2 is also constitutively
expressed in the brain (neurons, astrocytes, microglia, and endothelia), but can be
inducible under pathological conditions (74). In the brain, COX-2 acts as a key mediator
^ of inflammation, orchestrating a wide spectrum of brain injuries including excitotoxic
brain injury, cerebral ischemia, traumatic brain injury, and neurodegenerative disorders
(52). COX-2 can propagate the neuroinflammatory response and contribute to tissue
damage through the production of toxic prostanoids and reactive oxygen species (38).
COX-3 has also been reported in brain tissue (15), but is a splice variant of COX-1 with
unknown function (41).
COX-2 Orchestrates hnmunologic Responses After HI
COX-2, a well-established mediator of adult brain injury (38), is emerging as a
key player in neuroinflammation after hypoxic-ischemic brain damage in the neonate
(25). Peripheral immune cells such as T-lymphocytes, B-cells, and Natural Killer cells
have the capability to up-regulate COX-2 expression when activated (13). However,
immune cell infiltration into the brain parenchyma is thought to also play a beneficial role
through the production of neurotrophic factors (47). Activated monocytes, macrophages,
and neutrophils are the peripheral cell source for the neurotrophic factor, G-CSF.
Peripherally produced G-CSF can also enter the brain by crossing the intact blood-brain
barrier and binding to its receptor on neurons and glial cells (57,59). In the brain, G-CSF
has been shown to protect neurons and trigger neurogenesis (21). However, excessive
and/or prolonged activation of inflammatory mediators can decrease neurotrophic support
and neurogenesis in brain areas responsible for behavior and cognition (6,8,71). Studies
suggest COX-2 may mediate suppression of G-CSF, since inhibition of COX-2 was able
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to increase G-CSF production (35,36). This down-regulation of neurotrophic factors
contributes to secondary brain injury and cell death, after a bypoxic-iscbemic insult (69).
Emerging Therapeutic Modalities Targeting Inflammation
There are various therapeutic modalities that have attempted to modulate the
neuroinflammation that results from HI brain injury in neonates. These treatment options
have targeted various stages in the inflammatory cascade including COX-2 inhibition as
well as investigated the use of growth factors such as G-CSF. In the following
paragraphs, we will review these emerging therapeutic modalities and explore the various
research that have been conducted between 1970 and 2010 using relevant literature from
the National Library of Medicine and National Institute of Health Database
(www.pubmed.gov).
COX-2 Inhibition
To date, many studies have investigated the anti-inflammatory properties of
COX-2 inhibition and the benefits with improving neurologic outcomes after various
adult brain injuries. Yet smprisingly, only one study to date has investigated the use of
COX-2 inhibition on neonatal HI brain injury. The study led by Fathali et al. used
postnatal day ten rat pups to assess the effects of NS398, a known selective COX-2
inhibitor, on various neurologic outcomes after right eommon carotid artery occlusion
followed by 2 hours of hypoxia (25). The authors first described that COX-2 inhibition
limited morphologic damage, improved long-term functional deficits, reversed somatic
growth retardation, and lowered mortality rates after a hypoxic-ischemic injury in
neonatal rats. Noteworthy, COX-2 inhibition significantly reduced the expression of IL-6,
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a pro-inflammatory cytokine, and in tum, reduced the infiltration of inflammatory cells
such as macrophages and neutrophils, which suggests that the increased survivability and
neuroprotection provided by COX-2 may be mediated by a reduction in
neuroinflammation (25).
G-CSF Administration
G-CSF is a 20 kDa protein belonging to the c5dokine family of growth factors. It
is responsible for stimulating die proliferation, survival, and maturation of cells
committed to the neutrophilic granulocyte lineage by binding to specific G-CSF receptors
(65). In addition to its role in neutropenia, G-CSF has shown to be neuroprotective in
various brain injury models through direct apoptotic inhibition, inflammatory cell
modulation, and/or trophic effects on neuronal cells.
One of the first studies to investigate the anti-inflammatory properties of G-CSF
was conducted in 1992 by Gorgen et al. who looked at the role of G-CSF in gram
negative septic rodents (30). The study showed that G-CSF could interfere with TNF-a
production through a negative feedback signal. Later in 2005, both Gibson and Komie-
Kobayashi would also demonstrate the anti-inflammatory role of G-CSF by showing that
treatment could modulate the inflammatory response after injury (27,42). Specifically,
Komie-Kobayashi demonstrated G-CSF's ability to suppress inducible nitric oxide
synthase (iNOS) production and decrease activation of microglial cells expressing iNOS
- according to Western blot and immunohistochemistry analysis. Gibson on the other
hand, found that G-CSF treatment only suppressed the up-regulation of IL-IB mRNA and
had no effect on TNF-a and iNOS mRNA expression. Additionally, in models of
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peripheral mfection, G-CSF-induced JAK-STAT signaling was found to reduce TNF-a,
interleukin (IL)-1B, IL-2, IL-6, andIL-8 and elevate IL-16 receptor antagonists (34).
In terms of its neurotrophic capabilities, various studies have confirmed G-CSF as
an essential neurotrophic factor, noting its ability to stimulate the release of stem cells
from the bone marrow, promoting both neural repair and neural plasticity (65). A study
led by Shjoi et al. in Circulation (2004) found that ischemic stroke rats treated with G-
CSF, could mobilize autdlogous hematopoietic stem cells into circulation, enhance their
translocation into ischemic brain, and significantly improve lesion repair (64).
Additionally, in rat ischemic models, peripherally administered G-CSF was found to
enhance structural repair and function by increasing the number of newly generated
neurons in both healthy and ischemic subjects (60).
In neonatal HI, only two studies can be found on PubMed using the search criteria
"G-CSF and neonatal hypoxia ischemia". Unfortunately, none of the studies looked at the
role of G-CSF as an anti-inflammatory agent. Instead, the focus of attention was on the
role of G-CSF in apoptosis. The first study led by Yata et al., (2007) found that five
SOug/kg G-CSF post-treatment injections over four days could reduce apoptotic neuron
loss while increasing the expression of pro-survival signals (75). Specifically, the
investigators found that the anti-apoptotic protein Bcl-2 declined with injury and reversed
after treatment while the pro-apoptotic protein, Bax, increased following HI injury and
again, was reversed following G-CSF treatment. This is in line with another study
conducted by Kim et al., (2008) which found similar neuroprotective outcomes following
a single injection of 50ug/kg G-CSF after injury (40).
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Specific Aims
The interplay between infiltrating immune cells and brain resident cells during the
inflammatory response is dynamic and complex; in that neuro-immune crosstalk, by way
of specific molecular mediators, is responsible for both neurodestructive as well as
neuroprotective outcomes. Therefore, the neuroinflammatory response to neonatal CNS
insult may not comprise a uni-dimensional progression from ischemia to impairment, but
rather multiple processes of endogenous repair mechanisms are also initiated after injury.
We, therefore, propose identifying and suppressing the actions of molecular mediators
believed to be responsible for causation of signaling pathways that lead to a worsened
outcome and enhancing neurotrophic mediators responsible for recovery after a hypoxic-
ischemic insult. Herein, we tested the hypothesis that COX-2 mediates mechanisms of
brain injury and that G-CSF exerts structural and functional protection after neonatal HI.
The following specific aims are proposed to address our hypothesis (Figure 2).
Specific Aim 1 is to determine the optimal dosage and broad efficacy of COX-2
inhibition after HI brain injury. Our specific hypothesis is that multiple treatments of low-
dose or high-dose COX-2 inhibitor, over the first few days following HI brain insult, will
reduce brain damage, and improve long-term functional deficits, and somatic and
systemic organ growth.
Specific Aim 2 is to characterize the COX-2-dependent mechanisms involved in
brain-immune interactions after HI brain injury. Our specific hypothesis is that COX-2,
from spleen-derived immune cells, enhances neuroinflammation via IL-15 expression by
astrocytes. Elevated IL-15 inhibits the pro-survival protein PI3K in neurons, thereby
leading to caspase-3 activation and cell death. Interventions such as splenectomy.
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pharmacological inhibition of COX-2, a neutralizing antibody for IL-15, or a gene
silencer for natural killer cells are expected to provide neuroprotection against HI injury.
Specific Aim 3 is to determine the optimal regimen and broad efficacy of G-CSF
administration after HI brain injury. Our specific hypothesis is that multiple treatments
with the neurotrophic factor G-CSF, will improve long-term behavioral and
neuropathological recovery after HI.
The proposed work will: 1) introduce novel therapeutic modalities for attenuating
the morphological and neurological consequences of neonatal HI; 2) establish on a
molecular level the mechanistic basis by which peripheral immune cells interact with
resident brain cells and thereby propagate the neuroinflanunatory response and worsen
brain injury; 3) provide a basis for the clinical implication for targeting key inflammatory
pathways as an effective therapeutic option with long-temi benefits after a hypoxic-
ischemic brain injury.
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Figure 3. Schematic of Specific Aims. Aim 1 (pprple arrow) will examine the short- and
long-term effects of cyclooxygenase-2 inhibition after HI. Aim 2 (black arrow) will
determine the COX-2 mediated mechanisms and the cell types involved in neuro-immune
crosstalk. Aim 3 (blue arrow) will examine the long-term behavioral and morphological
effects of G-CSF treatment.
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Abstract
The development of brain inflammation largely contributes to neonatal brain
injury that may lead to a lifetime of neurologic deficits. The present study was designed
to investigate whether inhibition of cyclooxygenase-2 (COX-2), a critical component of
the inflammatory pathway, is neuroprotective in a neonatal rat model of cerebral
hj'poxia^ischemia (HI). DESIGN: Laboratory investigation. SETTING: University
research laboratory. Neonatal HI was induced in postnatal day-10 Sprague-Dawley rats
by ligation of the right common carotid artery followed by two hours of hypoxia (8% O2).
The pups in treatment groups were administered lOmg/kg (low dose) or 30mg/kg (high
dose) of a known selective COX-2 inhibitor (NS398). Animals were euthanized at three
time points: 72hrs, 2wks, or 6wks. Inflammation outcomes were assessed at 72hrs; brain
damage was assessed at 2- and 6wks along with other organs (heart, spleen). Detailed
neurobehavioral examination was performed at 6wks. Pharmacological inhibition of
COX-2 markedly increased survivability within the first 72hrs compared to untreated rats
(100% vs. 72%). Low- and high-dose NS398 significantly attenuated the loss of brain and
body weights observed after HI. Neurobehavioral outcomes were significantly improved
in some parameters with low dose treatment; while, high dose treatment consistently
improved all neurological deficits, hnmunohistochemical results showed a marked
decrease in macrophage, microglial, and neutrophil abundance in ipsilateral brain of
NS398 treated group along with a reduction in interleukin-6 expression. Selective COX-2
inhibition protected neonatal rats against death, progression of brain injury, growth
retardation, and neurobehavioral deficits after a hypoxic-ischemic insult.
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Introduction
A hypoxic-ischemic insult to neonates results not only in brain damage, but is also
associated with increased mortality and somatic growth retardation (1,2). There is no
effective treatment for neonatal hypoxia-ischemia (HI). Long-term effects of HI for the
survivors may include motor disability, cognitive dysfunction, and problems in learning
and behavior (3). The inflammatory response is particularly detrimental in the immature
brain, serving a key component in the progression of neonatal encephalopathy (4).
Cyclooxygenase-2 (COX-2), the inducible form of the enzyme and a key mediator
of inflammation, is critical in different forms of brain injury such as exeitdtoxic brain
injury, cerebral ischemia, traumatic brain injury, and neurodegenerative disorders (5).
Cerebrospinal fluid concentrations of prostaglandins (PG) such as PGE2 and PGI2, which
are downstream effectors of COX-2 enzyme, have been reported to be significantly
higher in children with perinatal hypoxia (6). Moreover, pharmacological inhibition of
COX-2 has been shown to be beneficial in brain and spinal cord-related injuries in adults
(7, 8). To date, no study has examined the effects of COX-2 inhibition against neonatal
Hl-induced brain injury.
Accordingly, we hypothesized that inhibition of COX-2-induced-inflammation
will reduce brain injury; improve neurological outcomes, and somatic and systemic organ
growth following HI in neonates. We examined the lasting effects of COX-2 inhibition
using two different doses of a selective COX-2 inhibitor, NS398, in a well established
neonatal HI model in rats. We also confirmed the presence of COX-2 in neuronal cells




Animal Groups and Operative Procedure
This study was in accordance with the National Institutes of Health guidelines for
the treatment of animals and was approved by the Institutional Animal Care and Use
Committee at Loma Linda University. Timed pregnant Sprague-Dawley rats were housed
with food and water available ad libitum. Postnatal day-10 pups were randomly assigned
to the following groups; sham, HI [Vehicle], HI+10mg/kgNS398 [NS-10], or
Hl+SOmg/kg NS398 [NS-30]. Each litter consisted of all groups. Pups were placed on a
surgical table maintained at 37®C and anesthetized by inhalation with isoflurane (3% in
mixed air and oxygen). Hl-groups had right common carotid artery permanently ligated.
After l.ShOurs (hrs) of recovery, pups were placed in a glass jar (submerged in a water
bath maintained at 37''C) perfused with 8% oxygen for 2hrs. Rats were euthanized under
general anesthesia [ketamine (80mg/kg)/xylazme (lOmg/kg)] by decapitation at 72hrs, 2-
and 6weeks (wks) post-HI.
Treatment Method
Some pups were treated intraperitoneally with a COX-2 inhibitor (NS398) at
either lOmg/kg or 30mg/kg dosage (Cayman Chemical, Ann Arbor, MI) diluted in 10%
dimethylsulfoxide (DMSO) and saline. Treatment consisted of six injections (1, 6, 24, 36,
48, and 60hrs) after hypoxia. Vehicle pups followed same injection regimen and
methodology, but administered 10% DMSO in saline.
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Evaluation of Brain Damage
Hemispheric weight loss has been used as the primary variable to estimate brain
damage in this animal model (9). At 2- and 6wks, the brain was removed, without prior
perfusion, and the hemispheres were separated by a midline incision and weired on a
high-precision balance (sensitivity ±0.001 g).
Measurement of Organ Weight
After removal of brain, the spleen and heart were isolated and detached from
surrounding tissue and vessels and weighed at the 6wk interval.
Assessment of Neurobehavioral Deficits
Rats were tested at 6wks and scored accordingly: 0 for immediate and correct
placement; 1 for delayed and/or incomplete placement; 2 for no placement. Scores
corresponded to raw values: 0 = raw value of 100; 1 = raw value of 50; 2 = raw value of
0. Methodology was as previously described (10) for the first six tests:
1. Postural Reflex: Assessed upper body posture and symmetry in forelimb
extension (11). Rat was held by tail and lowered to 10cm above table top.
2. Proprioceptive Limb Placing: Rat's head was tilted 45° upwards to avoid visual
and tactile contact with table. Dorsum of paw was pushed against table edge to
stimulate limb muscles and joints for forelimb placement onto table top.
3. Backpressure Towards Edge: Rat was moved from behind toward table edge
for assessment of forward limb placement.
32
4. Lateral Pressure Towards Edge: Rat was moved from ipsilateral or
contralateral side toward table edge for assessment of lateral and forward limb
placement.
5. Forelimb Placement: Rat was held facing table edge with visual and tactile
(whisker) contact with table, and assessed for forward limb placement onto
table top.
6. Lateral Limb Placement: Rat was held parallel to table edge with tactile
contact, and assessed for lateral limb abduction onto table top.
7. T-Maze: Assessed short-term or working memory (12). Rat was placed in the
stem (40x10cm) of maze and allowed to explore until an arm (46x10cm) of
maze was chosen. The sequence (10 trials) of left and right arm choices was
expressed as rate of spontaneous alternation (0%=no alternation,
100%=altemation at each trial).
8. Foot-fault: Assessed placement dysfunction of forepaws and motor
coordination, and is reliable in differentiating between ischemic and normal
rats (11,13). Rat was placed onto an elevated wire grid floor (20x40cm) for 2
minutes. Foot-faults were when a complete paw fell through openings.
Immvmohistochemistry with DAB Staining
Animals (n=5/group) were perfused with O.IM phosphate buffered saline (PBS)
and fixed with 10% paraformaldehyde (formalin) diluted in PBS, via trans-cardiac
approach 72hrs post-insult. The sectioned brain volume (5mm) encompassed dorsal
hippocampus. Every fifth section of the tissue block was collected, and from this set, 6
random, non-adjacent sections were stained and then observed. Special care was taken to
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analyze sections from the same levels of sectioning in different animals. Antigen retrieval
was done on slices (lOgm) by microwave irradiation in O.IM sodium citrate (pH=6) for
10 minutes. Diaminobenzidine (DAB) staining method (ABC Staining Kit, Santa Cruz
Biotech, Santa Cruz, CA) was implemented as previously described (14) for detection of
COX-2 expression in the ipsilateral cortex and CAl region of hippocampus. Antibodies
included goat anti-COX-2 (1:100) and donkey anti-goat secondary antibody (1:200). All
antibodies were obtained from Santa Cruz Biotech (Santa Cruz, CA), unless otherwise
stated. Controls for non-specific immunobistocbemical staining were done with omission
of the primary antibodies.
Westem Blotting of COX-2
Animals (n=5/group) were perfused (O.IM PBS) at 72brs post-HI. Ipsilateral
hemisphere was isolated then snap-frozen and kept at -80°C until analysis. Samples in
(300mg/mL) extraction buffer (50mM Tris-HCl buffer [pH 7.4] with ISOmM NaCl, 1%
Nomide P40, 0.1% sodium dodecyl sulfate (SDS), 0.1% deoxycholic acid, and 1%
PMSF) and 1% protease inhibitor were homogenized with a tissue homogenizer for a
total of 60 seconds (20x 3 sec pulses). The homogenate was eentrifuged (15000 g for 20
min), the supernatant of the extract was collected, and the concentration of the protein
samples was determined by Bradford assay (BioRad, Hercules, CA). All procedures were
performed at 4°C. 40pg sample of extracted protein with 2x loading buffer (62.5 mM
Tris-HCl [pH 6.8], 2% SDS, 25% glycerol, 0.01% Bromophenol Blue, and 5% p-
mercaptoethanol) were subjected to electrophoresis on 10% polyacrylamide SDS gel
(BioRad, Hercules, CA). Procedures were as previously described (15). Primary
antibodies were goat anti-COX-2 and rabbit anti-P-aetin. Incubation with donkey anti-
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goat and donkey anti-rabbit secondary antibodies was done, respectively. Bands were
detected by chemiluminescent kit (Amersham Bioscience, Piscataway, NJ) on X-ray film
(Kodak, Rochester, NY). Optical density was determined using NIH Image J software
and expressed relative to P-actin then to sham group.
Triple Fluorescent Labeling
Cerebral tissue was perfused (O.IM PBS), fixed (10% formalin), and sectioned
(5mm volume) at 72hrs for use in triple-fluorescent labeling. Primary antibodies were
goat anti-COX-2 (1:50), rabbit anti-IL-6 (1:50) with mouse anti-NeuN (1:100; Millipore
Corp., Billerica, MA). Tissue slices (10pm) were blocked with 5% donkey serum in PBS
at room temperature for 2hrs. Slices were incubated overnight at 4'^C, followed with
respective donkey secondary antibodies conjugated with fluorescent dyes for 2hrs at
room temperature in the dark, as previously described (16). Between incubations, three
washes of 5min were performed at room temperature with 0.01 M PBS (pH 7.4).
Controls for non-specific immunofluorescence staining were done with omission of the
primary antibodies. To test for tissue autofluorescence, some sections were processed
without the secondary antibodies. The ipsilateral cortex and CAl region of hippocampus
(n=5/group) were analyzed using a fluorescent microscope with digital camera
(OLYMPUS BX51, Melville, NY).
Inflammatory Cell Infiltration
Animals (n=5/group) were perfused (O.IM PBS) at 72hrs post-HI. Ipsilateral
hemisphere was isolated then snap-fi-ozen and kept at -80°C until analysis of interleukin-6
(IL-6) concentration by ELISA technique (Invitrogen Corp., Carlsbad, CA) and
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expressed as picogram per milligram protein. Samples in (300mg/mL) extraction buffer
(50mM Tris-HCl buffer [pH 7.4] with 0.6M NaCl, 0.2% Triton X-100, lOpl aprotinin,
Ipg/mL leupeptin, and ImM PMSF) and 1% protease inhibitor were homogenized, the
supernatant of the extract was collected, and the protein samples were assayed in
duplicate. Cerebral tissue was perfused (O.IM PBS), fixed (10% formalin), and sectioned
(5mm volume) for detection of inflammatory cell infiltration into ipsilateral cortex
(n=5/group). Rabbit anti-Ibal (1:100; Wako Chemicals USA Inc., Richmond, VA),
mouse anti-CD68 (1:100; Millipore Corp., Billerica, MA), or goat anti-MPO (1:100)
primary antibodies (Abeam Inc., Cambridge, MA) were added to sections (10pm).
Incubation methodology was same as in triple-fluorescent labeling. An estimation of the
amount of positive cells were defined as being low (<10 postive cells/per high power
visual field) or high (>10 positive cells/per high power visual field). As with all staining,
differences in levels of infiltrating cell markers were noted between groups by an
experimenter blinded to the treatment group of each section/slide observed.
Data Analysis
Data was expressed as mean ± SEM. One-way ANOVA and Tukey test were used
to determine significance in differences between means. Neurological scores were
analyzed using Means of Dunn Method (except T-Maze and Foot-fault tests); mortality
rates using chi square test; and assays using Dunnett's post hoc test with vehicle
designated as control. Significance was accepted at p < .05.
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Results
NS398 Protects Against HI-Related Lethality
Treatment with NS398 completely abolished the mortality evidenced in the
untreated group (0% vs. 28.12%). While nine vehicle pups died within the first 72hrs
following hypoxia; none of the NS398-treated pups died at any time during the
experiment, indicating that survival was specifically related to COX-2 inhibition. No
sham-operated pups died.
Cyclooxygenase-2 Blockade Maintains Body Weight After HI
Growth retardation is evident in both patients and experimental studies as a result
of hypoxia-ischemia (2, 17). Accordingly, somatic growth retardation was apparent in
vehicle rats at 2-, 3-, and 6wks (Figure 4) compared to sham. NS-30 significantly
improved body weight at the 6wk time-point. Drastic differences in fur texture and
appearance were detected as early as 2wks between treated and untreated rats (Figure 5).
NS398 Provides Neuroproteetion by Maintaining Brain Weight at Two Time Intervals
Hemispheric weight loss is an established estimate of brain damage in this animal
model (9). Severe brain atrophy, marked by a reduction in right to left hemispheric
weight ratio, was seen in vehicle rats at 2- and 6wks post-HI (Figure 6). Blockade of
COX-2 protected rats at both time-points.
NS398 Prevents HI-Related Systemic Organ Atrophy
A reduction in spleen size following middle cerebral artery occlusion (MCAO)
model of stroke (18) is correlated with the extent of brain damage (19). Our experiments
supported this observation in the HI neonatal model; with vehicle having a reduced
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spleen to body weight ratio (Figure 7). Treatment groups demonstrated a trend towards
maintaining spleen weight; however, no statistical significance was reached. Heart to
body weight ratio decreased in vehicle pups and was attenuated by NS-10 (Figure 7).























Figure 4. Long-Term Effect of COX-2 Inhibition on Body Weight. Postnatal day-10 rats
were induced with a hypoxic-ischemic (HI) event: ligation of the right common carotid
artery and 2-hours of hypoxia (8% 02) [Vehicle], then treated with 6 intraperitoneal
injections (1, 6, 24, 36, 48, and 60-hours post-hypoxia) of a selective cyclooxygenase-2
(COX-2) i^ibitor at either lOmg/kg [NS-10] or 30mg/kg [NS-30] dosage. Sham animals
had same anesthesia and surgical procedure, except that the common carotid artery was
not ligated. Vehicle animals had a significantly lower mean body weight at 2-, 3- and 6-
weeks, compared to sham (*p < .05). NS-30 had long-term lasting effects as it maintained
body weight compared to vehicle 6-weeks after HI (#p < .05). Only mean body weights







Figure 5. Photograph of Physical Appearance of Pups at 2-Weeks After HI Insult. A,
Differences in fur texture and appearance were detected between treated (T) and
untreated rats (U). B, Is a close-up picture demonstrating the somatic differences between
treated and untreated rats.
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Figure 6. Brain Atrophy 2- and 6-Weeks After HI Insult. NS-10 and NS-30 maintained
the gross morphology of the rat brains at 2- and 6-weeks post-HI. Right to left
hemispheric (RH:LH) weight ratio is representative of brain atrophy. At 2-weeks post-
insult, vehicle rats had a significantly reduced RH:LH ratio compared to sham (0.67 ± .05
vs. 1.00 ± .01). This was attenuated by NS-10 (0.88 ± .04) and NS-30 (0.93 ± .03). At 6-
weeks post-insult, vehicle rats had a significantly reduced RH:LH ratio compared to



































































































Figure 7. Heart and Spleen Weight 6-Weeks After HI Insult. Vehicle rats had a
significantly reduced heart to body weight ratio (0.0037 ± .0001 vs. 0.0041 ± .0001) and
spleen to body weight ratio (0.0026 vs. 0.0030 ± .0001) as compared to sham. Treatment
increased the heart to body weight ratio (NS-10:0.0045 ± .0001; NS-30:0.0040 ± .0001)
and the spleen to body weight ratio (NS-10: 0.0029 ± .0002; NS-30: 0.0029 ± .0002). Data
represent mean ± SEM; *p < .05 versus sham, #p < .05 versus vehicle. Numbers in bars
indicate animals/group.
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NS398 Prevents Neurobehavior Deficits
Motor, cognitive, and behavioral deficits can be a consequence of perinatal stroke
and may last a lifetime (20). Numbers in parenthesis denote mean raw score (Figure 8).
Sham demonstrated a successful performance (91.67) in postural reflex test; treatment
(78.57) significantly improved the gross asymmetry in posture and extension of forelimbs
seen in vehicle rats (8.33). In proprioceptive limb placing test, vehicle was delayed or
unable to place forelimbs onto table top (25.0). NS-30 entirely ameliorated the deficit
(100.0). In back pressure towards edge test, vehicle was delayed or unable to place limbs
forward (25.0); in contrast, NS-30 rats showed immediate placement (92.86). In lateral
pressure towards edge test, sham (91.67) had immediate lateral and forward limb
placement. This response was delayed or not present in vehicle (25.0), but markedly
improved by NS-30 (85.71). In forelimb placement test, vehicle was delayed or unable to
place limbs forward when allowed visual and tactile contact (33.33); NS-30 corrected
performance (92.86). In lateral limb placement test, vehicle rats were unable to abduct
limbs (8.33), a deficit improved by NS-30 (71.3). In T-maze, untreated animals showed a
significant decline in memory (reduced %altemations) that was improved by NS-10 and
more so by NS-30. Treatment also significantly attenuated the increased number of foot
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Figure 8. Dose-Dependent Effect of COX-2 Inhibition on Neurobehavior. A, Rats
received a raw score of 100 for immediate and correct placement; 50 for delayed and/or
incomplete placement; 0 for no placement (n = 9/group). Administration of NS-30
significantly improved all assessed behavior deficits; while, NS-10 significantly
improved deficits associated with the postural reflex test. Data represent *p < .05 versus
sham, #p < .05 versus vehiele. B, Vehicle rats alternated significantly less between the
two arms of the maze as compared to sham (18.52% ± 5.56 vs. 82.72% ± 2.69). Percent
alternations significantly rose with administration of NS-10 (53.09% ± 3.09) and more so
by NS-30 (81.48% ± 2.62). Data represent mean ± SEM; *p < .05 versus sham, #p < .05
versus vehicle, *p < 0.05 versus NS-10. C, Vehicle rats averaged the greatest number of
foot-faults (32.33 ± 3.49), while treatment significantly reduced the deficit (NS-10:12.29
± 1.70; NS-30:10.86 ± .86). Sham animals had an average of 10.67 ± 1.05 foot-faults.
Data represent mean ± SEM; *p < .05 versus sham, #p < .05 versus vehicle. Numbers in
bars indicate animals/group.
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NS398 Effectively Reduces Cyclooxygenase-2 Expression
Positive staining for COX-2 was detected by DAB stain (Figure 9). The negative
control showed no positive staining indicating that the primary antibody, and not non
specific immunohistochemical staining, was responsible for the positive signal. NS-30
qualitatively reduced post-HI COX-2 expression in both examined regions of the brain.
Higher magnification confirmed COX-2 localization in the cytoplasm of the cell. Western
blotting of COX-2 quantitatively supported significant differences between treated and
vehicle groups (Figure 10).
NS398 Reduces Cytokine Expression in the Brain
In the hippocampus (Figure 11) and cerebral cortex (Figure l2), there was strong
neuronal signal for COX-2 and IL-6 in vehicle. The opposite was seen in NS-30: marked
suppression of immunoreactive COX-2 and IL-6; while fluorescence was strong for
neurons.
COX-2 Inhibition Reduces Inflammatory Infiltration
IL-6 protein level was significantly increased in vehicle and substantially reduced
by NS-30 (Figure 13). Single-immunofluorescent labeling demonstrated a qualitative
increase in expression of microglia (Ibal), macrophages (CD68), and neutrophils (MPO)
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Figure 9. Diaminobenzidin (DAB) Staining of COX-2 Expression in the Cerebral Cortex
and Hippocampus. DAB stain for COX-2 in ipsilateral cerebral cortex (D-F) and CAl
region of hippocampus (G-I) qualitatively appears less in sham (A,D,G) and NS-30

































Figure 10. Western Blot Analysis of COX-2 Protein. A statistically significant reduction
in COX-2 expression in the ipsilateral hemisphere of NS-30 compared to vehicle (106.92
± 10.48 vs. 185.20 ± 19.54). Sham (120.88 ± 9.30) also had significantly less COX-2
expression than the vehicle group. Data represent *p < .05 versus sham, #p < .05 versus





















Figure 11. Interaction of COX-2 and IL-6 in Neuronal Cells of the Hippocampus. Six
non-adjacent coronal sections per brain (n = 5/group) were analyzed. Immunoreactivity is
shown of COX-2, lL-6 and NeuN in ipsilateral CAl region of hippocampus. Vehicle (A-
H) demonstrated strong neuronal fluorescence for COX-2 and lL-6; NS-30 (1-L)
demonstrated strong fluorescence fot NeuN, but weak fluorescence for COX-2 and lL-6.
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Figure 12. Interaction of COX-2 and IL-6 in Neuronal Cells of the Cerebral Cortex. Six
non-adjacent coronal sections per brain (n = 5/group) were analyzed. Immunoreactivity is
shown of COX-2, lL-6 and NeuN in ipsilateral cerebral cortex. Vehicle (A-H)
demonstrated a strong eo-localization of COX-2, lL-6, and NeuN. NS-30 (1-L) treatment













Figure 13. Immunosorbent Analysis of IL-6 Protein. Analysis by ELISA technique
showed significant increase of IL-6 in the ipsilateral cerebral hemisphere of vehicle rats
as compared to sham (22.61pg/mg ± 4.60 vs. 4.54pg/mg ± .77). Treatment with NS-30
markedly reduced IL-6 concentration (7.42pg/mg ± 1.44). Data represent *p < .05 versus











Figure 14. Immunofluorescent Photomicrographs of Microglial Activation, and
Macrophage and Neutrophil Expression in the Cerebral Cortex. Vehiele (A-F) pups
showed marked aetivation of niieroglia (Ibal; A and D), and infiltration of macrophages
(CD68; B and E) and neutrophils (MPO; C and F) in the ipsilateral eerebral cortex. NS-
30 qualitatively redueed expression of all three cell markers of inflammation (G-I). Sham
animals are shown in subsets of (A-C). Six non-adjaeent coronal sections per brain (n =
5/group) were analyzed. Brain slice in upper left eomer denotes the speeifie eortical area
the immunofluorescent pietures represent.
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Discussion
In the present study, we tested whether multiple treatments of low-dose or high-
dose COX-2 inhibitor, over Ihe first few days following brain insult, can reduce the
neurodevelopmental and/or somatic consequences of the injury. We showed for the first
time that COX-2 inhibition limited morphologic damage, improved long-term functional
deficits, reversed somatic growth retardation and lowered mortality rates after a hypoxic-
ischemic injury.
NS398 is a well known selective COX-2 inhibitor shown to have neuroprotective
effects in adult rat CNS injury models (7, 8). The dosage and treatment frequency (h.i.d)
of NS398 was adopted from cerebral ischemia studies in adult rats (7,21); however, the
high dose used in this study is slightly higher but comparable with that used in adult rat
models (10-20mg/kg). Both, NS-10 and NS-30 decreased the brain damage, as assessed
by brain weight, at both 2- and 6wks following brain injury. Trends suggested an
improvement in spleen weight following NS398 treatment, and significant improvement
in heart weight. Similarly, NS-30 consistently improved neurological deficits 6wks post-
insult. This was an important finding, considering past therapeutic modalities in
neonatology have resulted in unforeseen side effects (22,23). The partial protective
effects of NS-10 may be due to the developmental physiological status of the neonates.
Some clinical studies have shown that currently used COX-2 inhibitors such as celecoxib
are rapidly cleared (twice as fast) in children as compared to adults (24). Thus, the
pharmacokinetics of NS398 needs to be determined in neonatal experimental models.
High dose of NS398 also showed an improvement in body weight and other
somatic characteristics such as fur growth and quality. Clinical and experimental studies
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have shown that neonatal HI not only causes brain damage and neurological deficits but
also decreased somatic growth (2). The exact mechanism of how COX-2 inhibition
affects somatic growth after neonatal HI remains to be determined.
The anti-inflammatory properties of COX-2 inhibition attenuated brain injury
after neonatal HI. Over-expression of IL-6 in premature neonates is associated with
severe cerebral injury (25). Studies have shown an IL-6-mediated activation of microglia
around site of brain lesion; and a marked reduction of these effects in IL-6 deficient mice
(26). IL-6 is also associated with increased mortality, and is an independent predictor of
neurological deterioration following ischemic stroke (27,28). Inhibition of COX-2
significantly reduced the expression of IL-6; as well as showed a marked reduction in
infiltration of inflammatory cells such as macrophages and neutrophils and decreased
activation of microglia in the affected brain tissue. Thus, the neuroprotective effects and
increase in survivability demonstrated by COX-2 inhibition may be mediated by a
reduction in IL-6 and the subsequent inflammatory response.
Recently, selective COX-2 inhibitors have come under progressively intense
scrutiny due to an increased incidence of cardiovascular events among general
populations treated with COX-2 inhibitors. But, the evidence-at-large remains
contradictory and a host of studies both affirm and refute the putative cardiovascular
harms of COX-2 inhibitors, as reviewed by Salinas G, et al. Furthermore, the underlying
disease process and the type of cells involved may be pertinent factors in the overall
effect produced by inhibition of COX-2 (29,30). These selective inhibitors were
commonly prescribed as a chronic regimen for patients with inflammatory arthritis and
may thus produce entirely different effects when administered as acute regimens. Until
64
more definitive evidence is available, strong judgments about the harm-to-benefit ratio of
GOX-2 inhibitors should be withheld, as these may pre-empt valuable research into
untapped benefits for the general population. As evidenced in this study, selective
inhibition of COX-2 may be effective at protecting the injured neonatal brain, and be a
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The timeliness of the results presented in "Cyclooxygenase-2 inhibition provides
lasting protection against neonatal hypoxic-ischemic brain injury" by Fathali et al (1)
pertains to our current lack of treatments for improving functional deficits after acquired
brain injuries. Fathali and colleagues examine the relationships between perinatal
hypoxic/ischemic brain injury, C0X2 inhibition, and functional recovery, brain/body
morphometrics, and the inflammatory response induced after hypoxic brain injury in
neonatal rats. This work provides the basis for a better understanding of the molecular
effectors of neuroinflammation, and the effects of C0X2 inhibitors (coxibs) on those
effectors.
The results show an increase in C0X2 after brain injury that could be reversed by
early posthypoxia intervention with superanalgesic doses of the C0X2 inhibitor NS-398.
Consistent with other neuroprotection studies, this high-dose regimen reduced subacute
mortality from hypoxic/ischemic insult, stabilized chronic brain and body weight loss,
and improved ftmctional recovery in both neurologic and cognitive testing paradigms.
The evidence that prolonged elevations of COX2 expression and activity in the
brain is detrimental to outcomes is overwhelming reviewed in our earlier work (2). The
induction by and contribution of C0X2 to inflammation in the brain has been well
documented (3-5). However, there may be a case for an initial benefit of the acute COX2
response. In our brain injury studies, some data indicated (albeit indirectly) that acute
C0X2 activity may be beneficial (6). A few studies suggested prostaglandins may be
neuroprotective, but the preponderance of data show the opposite. The effects of
prostaglandin E2 in neural excitotoxicity models are limited to subacute reductions in
nuclear dye uptake; no protection was seen after 48 hrs (7). McCullough et al
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showed that the protective effects of prostaglandin E2 in primarily neuronal cell cultures
diminished significantly in cultured brain slices, likely because of the preservation of
astrocytic/neuronal interactions in organotypic cultures (8). Prostaglandin E2, likely via
/
the EP2 receptor, mediates reduced neuroinflammatory responses in cultured neurons, but
not in the presence of glia (8). Interestingly, one study has provided evidence that C0X2
prostaglandins, rather than reactive oxygen species, are responsible for C0X2-mediated
neurotoxicity (9). Importantly, the studies in which prostanoids (or their EP2 receptors)
are characterized as neuroprotective have never shown improvements in functional
outcomes.
By contrast, C0X2 inhibitors (e.g., 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulphonyl)phenyl-2(5H)-furanone [DFU] and nimesulide) reduced inflammation
and cell death, and improved behavioral recovery even when administered hours after
brain injury (6, 10-12). These findings provide evidence that C0X2 inhibitors have an
extended window of opportunity to protect vulnerably brain tissue fi-om secondary
damage.
Furthermore, our studies suggest that coxibs do more than just reduce
prostaglandins and fi"ee radicals. C0X2 inhibition after brain injury causes arachidonic
acid shunting, increasing hydroxyeicosatetraenoic acids and epoxyeicosatrienoic acids
levels in the injured brain (6, 13). These cytochrome P450 epoxygenase metabolites of
arachidonic acid are prime candidates for neuroprotective eicosanoids.
Hydroxyeicosatetraenoic acids have been shown to block glutamatemediated
excitotoxicity in cultured neurons (14). Epoxyeicosatrienoic acids block activation of
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inflammatory gene induction and reduce adhesion molecule expression in endothelial
cells both in vitro and in vivo (15).
It is apparent from this study by Fathali et al (1) that there are minimal age-related
differences in the benefit of coxibs to the injured brain. The coxib related risks of adverse
cardiovascular events (16 -21) are containable, if not insignificant, in the perinatal
population. Thus, this work also represents a potential therapeutic approach after
perinatal hypoxia that could improve the quality of life for children and their families.
Yet, the lack of treatments to block C0X2 or its induction specifically after brain
injury is due, in my opinion, to a popular collective expectation in this country of a life
free from risk, rather than to any failings of researchers to provide proof-of-principle or
in BioPharma's considerable efforts to develop and make available helpful tools for this
indication. There are still critical questions that remain with regard to the coxibs'
mechanisms of action, or whether there is any gender dependence in their utility (or risk
of adverse effects).
But if the current beneficial use of thalidomide after decades of disuse (due,
admittedly, to its dreadful side effects on human fetuses) is any example, it will be a long
time before drugs like rofecoxib or parecoxib can be revived. Only a grassroots
consciousness-raising effort by professional and patient advocates can change the
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Neuroimmune processes contribute to hypoxic-ischemic damage in the immature
brain and may play a key role in the progression of particular variants of neonatal
encephalopathy. The present study was designed to elucidate the mechanistic inter
relationship between astrocytes and neurons in response to infiltrating peripheral immune
cells after experimental neonatal hypoxia-ischemia (HI). Splenectomy was performed on
postnatal day-7 Sprague-Dawley rats 3 days prior to HI surgery; in which the right
common carotid artery was permanently ligated followed by 2 hours of hypoxia (8% O2).
Peripheral immune cells were found to largely contribute to cerebral infarct volume at 72
hours; body weight loss, brain and systemic organ atrophy, and neurobehavioral deficits
at 3 weeks. Quantitative analysis showed altered natural killer and T cell expression in
spleen and brain of ischemic animals. Elevations in cyclooxygenase-2 (COX-2)
expression by immune cells promoted interleukin-15 expression in astrocytes and
infiltration of inflammatory cells to site of injury; additionally, down-regulated the pro-
survival protein, PI3K, resulting in caspase-3 mediated neuronal death. Herein we
demonstrate with the use of pharmacological inhibitors/agonists and cell-tj'pe specific
siRNA that after neonatal HI, infiltrating peripheral immune cells may modulate
downstream targets of cell death and neuroinflammation by COX-2 regulated signals.
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Introduction
The inflammatory response, which is characterized, in part, by recruitment of
circulating immune cells, has been implicated as a core component of damage to the
immature brain following hypoxia-ischemia (HI) (1). Although many therapeutic
interventions have been explored to prevent and/or mitigate the inflammatory sequelae of
perinatal HI, few such interventions have proven clinically viable in the long run. One
explanation has been that the immunoinflammatory response is multifaceted, in that
activation of immune cells may have both detrimental and neuroprotective effects (2).
Increasing evidence suggests that a more integrative approach to therapy may resolve this
paradox (3,4). In theory, re-directing our attention from neuron-driven outcomes toward
the molecular mediators believed to orchestrate brain-immune cell interactions may prove
a more fruitful investigative approach in neonatal HI (5).
Cyclooxygenase-2 (COX-2), a well-established contributor to ischemic brain
injury (6,7), might serve as a prime candidate for such a molecular-mediated
investigation. In particular, COX-2 may mediate the mechanism by which activated
immune cells induce pro-inflammatory cjdokine production by astrocytes (8). Recent
data suggests that enhanced interleukin-15 (IL-15) expression in astrocytes is a major
propagator of inflammatory responses after central nervous system injury (9). Yet it still
remains to be determined whether astrocytes respond to GOX-2 effectors from infiltrating
immune cells by producing IL-15, which then further orchestrates the inflammatory
response and/or cell death in the immature brain.
Additionally, the degree of involvement from the innate immune system
correlates with the extent of neuronal damage in the post-ischemic tissue (2). Studies
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suggest dysfunction of the phosphoinositide-3-kinase (PI3K)/Akt survival pathway in
triggering apoptotic cascades in the hrain (10). However, it is unknown whether down-
regulation of the PI3K pathway and subsequent neuronal death in Hl-injured rats occurs
in response to COX-2 from infiltrating immune cells.
From the ischemic stroke model comes an indication that progression of hrain
injury is mediated by immune cells originating in the spleen (11). We hypothesized that
neurological outcomes in stroked neonatal rats can be ameliorated by targeting splenic
immune cells and their modulatory functions mediated by COX-2. To elucidate the
possible impact of the systemic inflammatory response on astroglia-neuron signaling, we
removed the spleen, the largest pool of peripheral immune cells prior to HI and studied
the short- and long-term outcomes in the neonate. We also used a gain and loss of
function approach (pharmacological activation or inhibition, respectively) for COX-2, a
neutralizing antibody for IL-15, and a gene silencer for natural killer (NK) cells in both
splenectomized and non-splenectomized rats to verify the role of COX-2 in splenic
immune cell responses following HI. Here, we identify infiltrating splenic immune cells
as a major source of enhanced COX-2 expression in the ischemic brain, and implicate
COX-2 for causation of signaling pathways in astrocytes and neurons that lead to a
worsened outcome.
Materials and Methods
L  Surgical Procedures
The protocol detailing this study was approved by the Institutional Animal Care
and Use Committee at Loma Linda University. Timed pregnant Sprague-Dawley rats
(Harlan Labs) were obtained and housed in individual cages under a 12 h light/dark
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cycle, with food and water available ad libitum. Splenectomy, on postnatal day-7 pups,
entailed a skin incision at the upper left quadrant of the abdomen, exteriorization of the
spleen through the incision, and cauterization of the blood vessels. Un-splenectomized
groups had the abdominal cavity opened, the spleen isolated, and then re-closed.
Postnatal day-10 pups were placed on a surgical table maintained at and
anesthetized by inhalation wifti isoflurane. Briefly, HI surgery (7) entailed permanent
ligation of the right common carotid artery using 5-0 surgical silk, followed by 1.5 h of
recovery, then placement in a glass jar perfused for 2 h with 8% oxygen. Rats were
sacrificed under general anesthesia by decapitation at 3 h, 3 d or 3 w post-HI.
Pharmacological Manipulation
Some postnatal day-9 pups were treated intraperitoneally with 30mg/kg COX-2
inhibitor (NS398; Cayman Chemical), or intraventricularly with O.Olmg/kg COX-2
agonist (4-HNE; Cayman Chemical) or with Ipl NK cell (CD 161; Invitrogen) siRNA.
Others were treated intraventricularly with 1.5pl IL-15 neutralizing antibody (Santa Cruz
Biotech) 1 h pre-HI.
Measurement of Infarct Size
Brain tissue was collected after trans-cardial perflision with O.IM phosphate
buffered saline; and cut at 2-nim intervals into 5 coronal sections and incubated in 2%
2,3,5-triphenyltetrazolium chloride (TTC) for infarct volume measurement (35).
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Evaluation of Organ Damage
Cerebral hemispheres (separated hy a midline incision) of animals and spleen of
un-splenectomized animals was isolated then weighed on a high-precision balance
(sensitivity ± 0.001 g).
Neurological Assessment
Rats were placed onto an elevated wire grid floor (36 x 13 in) for 2 min; foot
faults were noted when a complete paw fell through the bars for assessment of motor
coordination (36). Rat were placed at the base (40 x 10cm) of the maze for each trial and
allowed to explore xmtil an arm (46 x 10 cm) of the maze was chosen for assessment of
short-term or working memory (37). Sequence of choices over 10 trials was expressed as
the rate of spontaneous altemation. Methodology was as previously described for:
Postural Reflex, Proprioceptive Limb Placing, Lateral Pressure Towards Edge, and
Lateral Limb Placing (7). Animals scored 100 for immediate and correct paw placement;
50 for delayed and/or incomplete placement; 0 for no placement.
Immunofluorescence Analysis
Every fifth section of brain and spleen tissue was collected. From this set, six non-
adjacent coronal sections (10pm) from the same levels of sectioning in different animals
were used for fluorescent labeling (7). Antibodies used; CD161 (1:100; Serotec Co.), ..
CD3 (1:100; Serotec Co.), COX-2 (1:100; Santa Cruz Biotech), IL-15 (1:100; Santa Cruz
Biotech.), GFAP (1:100; Millipore), cleaved caspase-3 (1:100; Cell Signaling), NeuN
(1:100; Millipore), Ibal (1:100; Wako Chemicals), CD68 (1:100; Millipore), or MPO
(1:100; Dako). The absolute number of positive cells per square millimeter was counted
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in three peri-infarct regions of the ipsilateral cerebral cortex (7) or in three marginal zone
areas immediately adjacent to the white pulp of the spleen.
Western Blot Analysis
Homogenates of ipsilateral cerebral hemispheres were processed (7) for analysis
using antibodies against: COX-2 (1:300), CD161 (1:200), CD3 (1:200), PI3K (1:300;
Santa Cruz Biotech), pro caspase-3 (1:1000; Cell Signaling), cleaved caspase-3 (1:1000),
or beta actin (1:1000, Santa Cruz Biotech). Incubation with respective secondary
antibodies was done. Optical density was determined using NIH Image J software and
expressed relative to beta actin.
RT-PCR Analysis of NK Cells
Total RNA was isolated fi-om the ipsilateral hemisphere with TRIZOL reagent
and cDNA prepared fi-om 1 pg of total RNA using Superscript First-Strand Synthesis
System for RT-PCR (Invitfogen) (38). The thermal cycle profile of 35 cycles for PCR
amplification (GAPDH: 22 cycles) by means of thermocycler (iCycler; BIO-RAD) was:
1) denaturing (1 min, 94°C); 2) annealing primers (1 min, 55°C); and 3) extending
primers (1.5 min, 72°C). A portion of 10 pi of PCR products was electrophoresed in 2%
agarose gel in Tris-borate-EDTA buffer. Densities of bands were determined by Bio-Rad








Assessment of Cell Death
I
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick-end labeling
(TUNEL) method was used according to manufacturer's instructions (Roche Diagnostics-
Applied Science). Sections were mounted with anti-fade mounting medium (Molecular
Probes) under glass cover-slips, and digital microphotographs were taken separately for
each stain and merged using Magnafire software (Optronics).
Data Analysis
Observers were blind to the actual animal groupings. Results were expressed as
mean ± SEM. One-way ANOVA Holm-Sidak correction were used to determine
significance in differences between means. Kruskal-Wallis ANOVA followed by Dunn's
test was used for neurobehavioral analysis. When only two groups were available for
comparison, the impaired Student's r-test was implemented. P < 0.05 was taken as
significant.
Results
Splenectomy Attenuates Hl-Induced Cerebral Infarct
The spleen contains the largest reservoir of immune cells (11). To detect whether
the spleen is the major source of peripheral immune cells that infiltrate the ischemic brain
and contribute to cerebral infarction after HI, we quantified primary (3 h post-HI) and
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Figure 15. Primary and Secondary Brain Injury Expressed as Percent Infarct Volume.
Infarct volumes at 3 hours and 72 hours in splenectomy (SPLN), intact spleen with
hypoxia-ischemia (INT+Hl), and splenectomy with HI (SPLN+Hl) rats. *P < 0.001
versus splenectomy, ̂P < 0.001 versus intact spleen + HI - 72hrs. Data represent mean ±
SEM. One-way ANOVA with Holm-Sidak correction. Numbers in bars indicate
animals/group.
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(Figure 15). Removal of the spleen prior to HI had no effect on primary infarct (6.19 ±
1.11 vs. 6.50 ± 0.77), but significantly reduced secondary infarct (10.45 ± 2.94 vs. 35.93
± 1.69). Splenectohiized animals with no brain injury are shown as a control.
Splenectomy Attenuates Hl-Induced Extended Brain Damage
In order to determine the role of the spleen in long-term Hl-related brain damage,
we used reductions in spleen size (12) and hemispheric weight (13) as parameters for
brain damage. Hl-injured rats had significant spleen and brain atrophy compared to sham
animals 3 w post-HI (Figure 16). Comparisons of right to left hemispheric weight showed
significant attenuation of brain loss in HI rats with prior splenectomy (0.85 ± .03 vs. 0.72
± .04). Brain weight ratios of splenectomized animals without brain injury were not
significantly different than sham (0.99 ± .01 vs. 0.98 ± .01).
Splenectomy Improves Short- and Long-Term Body Weight After HI
Body weight gain post-HI is an indicator of general well-being (14). Accordingly,
we measured body weight gain over the first 3 d after HI insult and found Hl-injured rats
with an intact spleen gained less weight during the acute phase as compared to their
splenectomized counterparts (Figure 17). Next, weekly body weights were taken to
determine if these somatic differences had lasting effects (Figure 18). The HI rats with an
intact spleen were unable to catch up to the weight of sham rats for the entirety of the

































































































































































































Figure 16. Long-Term HI-Related Brain Damage Assessed by Spleen and Brain
Weights, (a) Spleen to body weight ratio of sham and intact spleen with HI rats at 3
weeks. P < 0.05 versus sham (b) Right to left hemispheric (RH:LH) weight ratio
representing brain atrophy at 3 weeks. *P < 0.001 versus sham, *P < 0.001 versus intact
spleen + HI. Data represent mean ± SEM. Unpaired Student's Mest (a); one-way
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Figure 17. Acute Body Weight Gain. Daily body weight gain of animals during the first
3 days after HI insult. *P < 0.001 versus sham, *P < 0.001 versus intact spleen + HI. Data
represent mean ± SEM. One-way ANOVA with Holm-Sidak correction.
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Figure 18. Weekly Mean Body Weight. Weekly mean body weight of animals over 3
weeks. Week 1: *P < 0.01 versus sham, ̂  < 0.01 versus intact spleen + HI; Week 2 and
3: P < 0.001 versus sham, ̂P < 0.001 versus intact spleen + HI. Data represent mean ±
SEM. One-way ANOVA with Holm-Sidak correction.
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Splenectomy Improves Hl-Induced Neurological Behavior Deficits
- Lifetime consequences of perinatal HI may include motor, cognitive, and
behavioral deficits (15). Several fimctional tests were used to evaluate the spleen's role
on long-term neurological behavior (Figure 19). When the spleen was intact, an ischemic
event resulted in a significant decline in motor coordination (Foot-fault: 33.33 ± 2.39),
memory (T-maze: 34.57% ± 4.70), and sensory function (Proprioceptive Limb Placing:
22.22 ± 8.78); while, prior removal of the spleen improved these outcomes (19.99 ± 2.77,
70.37% ± 3.21, and 83.33 ± 11.79, respectively). Additionally, HI rats with an intact
spleen demonstrated significant asymmetry in posture and extension of forelimbs
(Postural Reflex: 50.00), and reduced ability for correct placement of limbs (Lateral
Pressure: 22.78 ± 8.78; Lateral Limb Placing: 38.89 ± 13.89). Although splenectomy
prior to HI appeared to improve these deficits (77.78 ± 8.78, 66.67 ± 11.79, 77.78 ± 8.78,
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Figure 19. Neurological Behavior 3 Weeks After HI Insult. 'P < 0.05 versus sham, **P <
0.01, P < 0.001, P < 0.05 versus intact sple(
Kruskal-Wallis ANOVA with Dunn's correction.
en + HI. Data represent mean ± SEM.
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Cerebral Ischemia Alters Expression of Immune Cells in Spleen and Brain
Leukocytes are major effectors of damage after cerebral ischemia (16,17).
However, the contributions of peripheral immune cells to the ischemic neonatal brain are
unclear (18); and due to the vast differences in immune response between neonates and
adults, much of the insight obtained from adult studies cannot be inferred to be the same
in the immature brain (19). Accordingly, we sought to determine the leukocyte subsets
possibly released by the spleen (Figure 20) and found there to be a signifieant reduction
in immunoreactive-NK (1923 ± 175 cells/mm^ vs. 5381 ± 244 cells/mm^) and T (3010 ±
202 cells/mm vs. 4326 ±233 cells/mm ) cells after HI compared to sham. The same
trends between groups were also observed after quantitative analysis (NK: 65.02 ± 12.78
vs. 101.50 ± 2.10; T: 65.43 ± 5.24 vs. 100.00 ± 5.31). Next, we verified whether the
spleen is a major source of invading leukocytes in the post-ischemic brain (Figure 21).
Results indicated rats with an intact spleen had increased NK (186.67 ± 29.52 cells/mm^
vs. 28.00 ± 12.52 cells/mm^) and T (93.33 ± 11.81 cells/mm^ vs. 23.33 ± 8.61 eells/mm^)
cells after HI compared to sham; while prior splenectomy significantly reduced these cell





























































Figure 20. Natural Killer (NK) and T Cell Populations in Spleen Tissue, (a) NK and T
immunoreactive cells from sectioned spleen tissue between dotted lines of sham and
intact spleen with HI (INT+HI) rats. Scale bar, 60 pm. (b) Absolute number of NK and T
cells per square millimeter region in three marginal zone areas of the spleen immediately
adjacent to the white pulp (n = 6/group). NK: **? < 0.001 versus sham, T: *P < 0.01
versus sham, (c) Splenic tissue probed for NK (CD161) and T (CDS) cell expression,
relative to beta actin, on western blots. NK (n = 4/group): *P < 0.05 versus sham, T (n =
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Figure 21. Natural ICiller (NK) and T Cell Populations in Brain Tissue, (a)
Immunofluorescent evaluation of NK and T cell populations in ipsilateral cerebral cortex
(within dotted region) of sham, INT+Hl, and splenectomy with HI (SPLN+HI) rats. Scale
bar, 300 pm (panels I,K) or 30 pm (panels J,L). (b) Absolute number of NK and T cells
per square millimeter (n = 6/group). *P < 0.001 versus sham, *P < 0.001 versus intact
spleen + HI. Data represent mean ± SEM; one-way ANOVA with Holm-Sidak
correction.
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Splenic Immune Cells May be a Major Source of COX-2 in HI Brain
COX-2 is a major effeeter of ischemic cerebral injury (6,7). Therefore, we sought
to determine the contribution of the spleen on COX-2 expression in the Hl-injured brain
(Figure 22). Results showed that COX-2 expression was elevated in HI rats with an intact
spleen, hut significantly suppressed by prior splenectomy. To verify the efficacy of the
inhibitor (NS398) and agonist (4-HNE) used in our experimental studies for suppressing
and upregulating COX-2, respectively; the pharmacological agents were administered to
Hl-induced rats with or without a spleen. NS398 to HI rats with an intact spleen
significantly reduced COX-2 density compared to their untreated counterpart; hut, there
was no significance between NS398-treated or -untreated HI rats with prior splenectomy.
4-HNE significantly enhanced COX-2 expression in Hl-injured groups, although less so
in splenectomized rats.
"\
COX-2 May Contribute to Hl-Induced Body Weight Reduction
To elucidate whether the low body weights of HI rats with an intact spleen were
COX-2-mediated, rats were administered NS398 or 4-HNE on postnatal day-9 followed
one day later by sham- or Hl-surgery. We found NS398 maintained body weights after
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Figure 22. Western Blot Analysis of COX-2 Protein. COX-2 protein levels relative to
beta actin in the ipsilateral hemisphere of rats. Comparisons made after administration of
COX-2 inhibitor (NS398) or agonist (4-HNE) (n = 5/group; interventions: n = 4/group).
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Figure 23. Mean Body Weight of Pups Administered COX-2 Inhibitor (NS398) or
Agonist (4-HNE). Daily mean body weight of rats administered NS398 (left-side of
figure) or 4-HNE (right-side of figure) on postnatal day 9 followed by HI insult on day
«]c ^
10. Individual body weights were compared for statistical analysis. P < 0.05, P < 0.01.
Data represent mean ± SEM; one-way ANOVA with Holm-Sidak correction.
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COX-2 Co-Localizes With Immune Cell Subsets After HI
To determine whether the immune cell subsets infiltrating the isehemie brain were
involved in expressing COX-2, double-immunofiuorescence was performed on brain
sections for comparison of splenectomized and un-splenectomized Hl-injured rats (Figure
24). Results showed elevated COX-2-expressing NK and T cells in brains of HI rats with
an intact spleen (79.33 ± 13.36 and 56.00 ± 7.23 cells/mm^, respectively) eompared to
sham (32.67 ±13.36 and 14.00 ± 6.26 eells/mm^, respectively). Splenectomy prior to HI
significantly reduced NK/COX-2 (14.00 ± 6.26 eells/mm^) and T/COX-2 (28.00 ± 7.23
cells/mm^) populations. Since NK cells appeared to be the majority in the isehemie
tissue, NK siRNA was administered to verify its role on COX-2 expression. The efficacy
of the siRNA was provided by RT-PCR (Figure 25) and further analysis demonstrated



























































































Figure 24. Quantification of COX-2 Immunoreactive Natural Killer (NK) or T Cells.
Immunohistochemical analysis of ipsilateral cerebral cortex double-stained with
antibodies against NK cells and COX-2 or T cells and COX-2. Scale bar, 30 )am.
Absolute number of NK and T cells co-expressing COX-2 per square millimeter (n =
6/group). P < 0.01 versus sham, *P < 0.01 versus intact spleen + HI. Data represent mean
± SEM; one-way ANOVA with Holm-Sidak correction.
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Figure 25. RT-PCR Analysis of Natural Killer Cell (CD161) mRNA. NK cell mRNA
expression levels in rats pre-treated with scrambled RNA or NK (GDI61) small
interfering (si) RNA (n = 6/group). *P < 0.001. Data represent mean ± SEM; one-way
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Figure 26. Western Blot Analysis of COX-2 Protein in Pups Administered Natural Killer
Cell (GDI61) siRNA. COX-2 protein levels relative to beta actin in the ipsilateral
hemisphere of rats pre-treated with CD 161 siRNA (n = 4/group). Data represent mean ±
SEM; one-way ANOVA with Holm-Sidak correction.
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COX-2 May Promote IL-15 Expression by Astrocytes
By-products of reactive astrocytes play a key role in regulating the extent of the
immxme response (20). Therefore, we sought to elucidate whether peripheral immune
cells propagate the neuroinflammatory response by inducing expression of the pro-
inflammatory eytokine IL-15 in astrocytes (Figure 27). Isehemie cortical areas of rats
with an intact spleen revealed elevated IL-lS-immunoreactive astrocytes, but a marked
reduction was evident in splenectomized animals. Next we verified whether these
differences were COX-2-mediated, and found suppressed IL-15 immunoreactivity in
NS398-treated HI animals. While 4-HNE enhanced IL-15-expressing astrocytes, co-
loealization was substantially less in HI rats with prior splenectomy. To determine the
role of IL-15 in Hl-induced damage, we evaluated infarct volume (Figure 28) and body
weights (Figure 29) of rats after administration of IL-15 neutralizing antibody and found
significant improvements in both parameters.
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Figure 27. Quantification of Interluekin-15 (IL-15) Inununoreactive Astrocytes. (a)
Inununofluorescent evaluation of IL-15 expression by astrocytes (GFAP). Comparisons
made after administration of COX-2 inhibitor (NS398) or agonist (4-HNE). Scale bar,
300 pm (panel C) or 30 pm (subset panel C and others), (b) Absolute number of
astrocytes co-expressing IL-15 per square millimeter (n = 6/group). *P < 0.05, **P <
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Figure 29. Daily Weight Gain of Pups Administered Interleukin-15 (IL-15) Neutralizing
Antibody Prior to HI. Daily body weight gain, during first 3 days post-HI, of rats
administered IL-15 neutralizing antibody. Data represent mean ± SEM; One-way
ANOVA with Hohn-Sidak correction. *P < 0.001 versus intact spleen + HI.
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COX-2 May Mediate the Local Inflammatory Response
Microglia, macrophage, and neutrophil numbers in the ischemic hemisphere are
greatest 3 d post-stroke (2). To determine the role of peripheral immune cells in
propagating inflammatory cell infiltration and microglia activation at the site of injury;
single-immunofluorescent staining in the ipsilateral cerebral cortex were done for
markers of microglia, macrophages, and neutrophils. We found Hl-induced rats with an
intact spleen showed elevated expression of these inflammatory cells, while prior
splenectomy suppressed this outcome (Figure 30). NS398 to Hl-injured rats with an
intact spleen also reduced inflammatory cell abundance. On the other hand, 4-HNE
significantly increased neuroinflammation although in splenectomized rats there were
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Figure 30. COX-2 Mediated Inflammatory Cell Abundance in tbe Cerebral Cortex, (a)
Immunofluorescent evaluation of microglia (Ibal) activation, and expression of
macrophages (CD68) and neutrophils (MPO) in cerebral cortex of rats. Comparisons
made after administration of COX-2 inhibitor (NS398) or agonist (4-HNE). Scale bar,
300 pm. (panel C) or 30 pm (subset panel C and others), (b) Absolute number of
microglia, macrophage, and neutrophil abundance per square millimeter (n = 6/grbup).
Data represent mean ± SEM; One-way ANOVA with Holm^Sidak correction. *P < 0.001.
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COX-2 May Promote Cell Death Pathway
To determine whether infiltrating immune cells in the injured brain exert
detrimental effects by down-regulating specific pro-survival cellular signals, the
expression of PI3K was measured and, found to be significantly reduced in Hl-injured
animals with an intact spleen compared to those with prior splenectomy (Figure 31). NK
cells may be responsible for these differences as PI3K levels were equal between groups
after NK cell siRNA administration. Next, we determined whether IL-15 regulates PI3K
expression and found that IL-15 inhibition normalized PI3K levels for Hl-injured rats
with an intact spleen. To then investigate the molecular mechanism by which decreased
PI3K may have an apoptotic effect, we quantified pro- and cleaved-caspase 3 levels. We
found that Hl-injured rats with splenectomy had higher levels of pro-caspase-3 and lower
levels of the activated form of the protein compared to those with intact spleen (Figure
32). Moreover, we found that NS398 to HI rats with an intact spleen decreased the
expression of activated caspase-3 while the reverse was shown with 4-HNE.
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Figure 31. Western Blot Analysis of PI3K Protein. Phosphoinositide-S-kinase (PI3K)
protein levels relative to beta actin in the ipsilateral hemisphere of rats. Comparisons
made after administration of NK cell siRNA (si) or IL-15 neutralizing antibody (A) (n =
5/group; interventions: n = 4/group). Data represent mean ± SEM; one-way ANOVA
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Figure 32. Western Blot Analysis of Pro- and Cleaved-Caspase 3. Pro-caspase 3 and
cleaved caspase 3 protein levels relative to beta actin in the ipsilateral hemisphere of rats.
Comparisons made after administration of COX-2 inhibitor (NS398; NS) or agonist (4-
HNE; HN) (n = 5/group; interventions: n = 4/group). Data represent mean ± SEM; one
way ANOVA with Holm-Sidak correction. *P < 0.05, **P < 0.01, ***P < 0.001.
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Splenectomy Attenuates Caspase-Mediated Neuronal Death
An immunofluorescent study was done to examine whether neuronal cells were
involved in the caspase-mediated pathways induced by infiltrating immune cells. We
fmmd elevated cleaved caspase-3-expressing neurons in HI rats with an intact spleen as
compared to splenectomized rats (Figure 33). TUNEL analysis was done to determine
whether the effects on cell death were limited to neurons (Figure 34). Results showed that
HI rats with an intact spleen abundantly expressed TUNEL-positive cells localized in the
nucleus of neuronal cells and not astrocytes, thereby further supporting our proposed
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Figure 33. Quantification of Cleaved-Caspase 3 Immimoreactive Neuronal Cells.
Immunofluorescence stain for cleaved caspase-3 (clvd casp-3) in neurons (NeuN) of the
ipsilateral cerebral cortex. Scale bar, 300 pm (panel C) or 30 pm (subset panel C and
others). Absolute number of neurons co-expressing cleaved caspase-3 per square
millimeter (n = 6/group). Data represent mean ± SEM; one-way ANOVA with Holm-
Sidak correction. ***P < 0.001.
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Figure 34. TUNEL-Positive Cells in the Cerebral Cortex After HI Insult. Terminal
deoxynueleotidyltransferase-mediated dUTP-biotin nick-end labeling (TUNEL) with
markers for neurons (NeuN) and astrocytes (GFAP) (n = 6/group). Scale bar, 300 pm
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Figure 35. Proposed Mechanism with Sites of Intervention.
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Discussion
In this study we characterize the mechanistic interaction between the components
of the glia-neuron unit in response to immigrating peripheral immune cells after a
hypoxic-ischemic insult in the neonatal rat. Our major new finding is that spleen-derived
immune cells serve as principal mediators of infarct growth, long-term brain atrophy,
somatic restriction, and ftanctional deterioration following neonatal HI; and propose an
underlying mechanism by which infiltrating immune cells may cause these
neuropathological outcomes.
We evidenced marked reductions in infarct volume in Hl-injured animals with
prior splenectomy as compared to animals with an intact spleen. Since the operative
variable was splenectomy, our data in a compelling way links HI inflammatory responses
to splenic immune cell population. Previous reports indicated that inflammatory
responses are a core component in the sequelae of neonatal HI, comprising a significant
portion of secondary brain injury (21). In this study we demonstrate that the magnitude of
mflammatory response in the ischemic immature brain may be proportional to the extent
of peripheral immune cell invasion and suggest that these cells employ COX-2 to
modulate astrocyte-neuron signaling and the extent of injury.
More specifically, we have found that the influx of COX-2 expressing immune
cells enhances astrocytic IL-15 production and caspase-3-mediated neuronal death, which
in sum may propagate brain damage. While various brain cells can produce COX-2,
splenic cells appear to be a crucial source as splenectomy dramatically reduced COX-2
expression in the ischemic brain. Of the many spleen-derived immune cells that may be
involved in COX-2 production, we focused on NK cells which are a component of the
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innate immune system, and T cells which are typically part of the adaptive immune
system. Indeed our findings suggest a substantial involvement of NK cells in the
production of COX-2 after HI; however to verify this, a gene silencer against NK cells
was administered. Results demonstrated that knocking down CD161 of NK cells restored
baseline levels of COX-2 in brain injured animals with an intact spleen, further
suggesting NK cells may be a key spleen-derived cell type involved in COX-2 production
and the progression of brain damage.
Inflammation in the central nervous system, a major component of brain damage,
is maintained by cytokine cascades triggered by reactive astrocytes and microglia
(22,23). Recent evidence implicates IL-15 as a significant activator of resting microglia
after LPS stimulation, with astrocytes being a major source of IL-15 (9). In line with
these findings, we observed an increase in IL-15 expression by astrocytes, as well as
increases in neutrophil and macrophage abundance and microglia activation in brain
injured animals. On the other hand, splenic removal prior to Hl-insult markedly
attenuated these associated changes. This led us to believe that down-stream COX-2
effectors from splenic immune cells may be potent stimulators of IL-15 production by
binding to E-prostanoid receptors, which are present on astrocytes (24). In fact,
pharmacological blockade of COX-2 afforded the same reductions in IL-15 mediated
inflammatory propagation, as did splenectomy in the Hl-injured rats. These COX-2
regulated signaling patterns were further supported when opposite effects (enhanced IL-
15 and inflammatory propagation) were seen in Hl-injured rats with administration of 4-
HNE, a COX-2 agonist. It is important to note that 4-HNE can induce COX-2 mRNA and
protein expression in many different cell types (25,26). This may explain the 4-HNE
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induced elevation in COX-2 expression, inereases in astroeytic IL-15 expression and
inflammatory cell infiltration in the ischemic hemisphere, irrespeetive of splenectomy.
Although, other lymphocyte-exclusive by-produets, such as interleukin-2 (IL-2),
have also been shown to stimulate IL-15 production (27), experimental studies using IL-
2-deficient mice have reported no ehanges in immune function (28). Previous studies
showed that IL-15 plays a major role in inflammatory infiltration and activation of NK
cells (29,30). Concordantly, our study shows that COX-2 bloekade, which results in
reduced IL-15 brain expj-ession, also decreases infiltration of inflammatory cells.
Splenectomy, by eliminating a large source of COX-2 formed by invading NK immune
cells, may reduce IL-15 expression and the subsequent inflammatory response thereby
reducing brain injury and improving functional performance.
Modulation of COX-2 is important not only for regulation of neuroinflammation,
but chronieally elevated levels of IL-15 may also lead to neuronal death (9).
Consequently, we found that inhibition of IL-15 in the ischemic brain lead to increased
PI3K levels. Moreover, eo-culture studies incubated with COX inhibitors suppress glial-
mediated paracrine damage to neurons (24). In line with these studies, we found that a
reduction in COX-2-expressing NK cells correlated to increased PI3K levels and
decreased eleaved caspase-3 expression in neurons. Furthermore, the Hl-induced
elevations in cell death appear to be neuron-limited and not include astrocytes. This
supports our notion that astrocytes are aetively participating in production of down
stream effectors that induce neurodegeneration. Future studies are needed to determine
the exact mechanism of COX-2-mediated increases in cell death proteins after HI,
including IL-15 binding to the IL-15/PI3K neuronal complex (27).
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In the present study we confirm that the secondary brain injury in the Hl-induced
neonate includes apoptosis (31) and activation of local inflammation (32) both of which
may be triggered by spleen-derived NK cells. Depletion of splenic immune cells through
splenectomy led to a lasting and robust improvement across most neurobehavioral tasks.
However, it cannot be ruled out that the splenectomy-induced neuroprotection afforded 3
w post-Hl may, in fact, not be a direct effect of there being less COX-2 producing
immune cells to infiltrate the ischemic brain in the acute stage of HI. At later stages,
studies have shown that adaptive immune responses promote production of neurotrophic
factors involved in remodeling the post-ischemic brain (33). Therefore, a possible
explanation for the long-term benefits in our study could be that immunologic cells
involved in enhancing brain plasticity within weeks after HI may have migrated from
other lymphoid organs in the absence of the spleen (34). Nevertheless, this amelioration
of long-term outcomes provides the basis for the clinical relevance of this study.
In summary, we have demonstrated that the spleen appears to be a major source of
peripheral immunologic cells that infiltrate and exacerbate brain damage through their
interactions with astrocytes and neurons. Consequently, a depletion of splenic cells offers
lasting protection against Hl-induced neonatal brain injury. We also identified a
previously unrecognized COX-2-dependent link between splenic immune cells and
signaling pathways controlling cellular inflammatory targets and neuronal death after
neonatal HI. We believe that the findings of this study provide mechanistic basis for
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Abstract
Hypoxia-ischemia (HI), as a major cause of fetal brain damage, has long-lasting
neurologieal implications. Therefore, therapeutic interventions that attenuate the
neuropathological outcome of HI while also improving the neuroflinetional outcome are
of paramount elinieal importance. The aim of this study was to investigate the long-term
functional and protective actions of granulocyte-colony stimulating factor (G-CSF)
treatment in an experimental model of cerebral HI. Postnatal day-7 Sprague-Dawley rats
were subjected to HI surgery whieh entailed ligation of the right common carotid artery
followed by 2 hours of hypoxia (8% O2). Treatment consisted of subcutaneous injection
of G-CSF at 1 hour after hypoxia followed by an additional one injeetion per day for 5
days (6 total injections) or for 10 days (11 total injections). Animals were euthanized 5
weeks post-insult for extensive evaluation of neurological deficits and assessment of
brain, spleen, heart, and liver damage. G-CSF treatment promoted somatic growth, and
prevented brain atrophy and imder-development of the heart. Moreover, reflexes, limb
plaeing, muscle strength, motor coordination, short-term memory, and exploratory
behavior were all significantly improved by both G-CSF dosing regimens. Long-term
neuroprotection afforded by G-CSF in both morphologieal and functional parameters




Neonatal hypoxia-ischemia (HI) is a major cause of long-term neurological
disturbances, such as behavioral alterations and motor deficits including cerebral palsy,
mental retardation, and epilepsy [1,2]. In spite of advancements in obstetric and neonatal
intensive care, HI brain damage with severe neurological sequelae remains an important
clinical problem [3]. Therefore, the efficacy of potential neuroprotective treatments on
long-term functional brain recovery is of significant translational importance.
Granulocyte-colony stimulating factor (G-CSE), a neurotropic factor involved in
proliferation, differentiation, and fimctional integration of neural cells [4], is a
neuroprotective agent in a wide spectrum of experimental models of neurological disease
[5-11]. Protection ranges from reductions in infarct size during the acute phase to
attenuation of long-term fimctional neurological deficits [12,13]. Promotion of
neurogenesis and angiogenesis are processes by which G-CSF exerts beneficial effects on
adult post-stroke recovery [14-16]; however, due to the vast differences in the
pathophysiology of immature and adult brains, data gathered from adult studies do not
necessarily infer synonymous outcomes in neonatal medicine. Therefore, the effects of
G-CSF treatment on cerebral infarct volume at 2 weeks (w) [17] and cerebral atrophy at 3
w [6] after HI have previously been explored. Although no study as of date has examined
whether these G-CSF-induced morphological benefits translate into improvements to
sensorimotor deficits and memory 5w after neonatal HI; and whether there is an additive
benefit against long-term brain and systemic organ atrophy provided with additional
administration of G-CSF.
144
Accordingly, we hypothesized that G-CSF has lasting neuroprotective actions hy
improving both morphological and behavioral endpoints after Hl-injury in neonatal rats.
We used two different dosing regimens to implicate the neurotrophic capabilities of G-
CSF to be responsible for the structural preservation and improved functional outcome.
Materials and Methods
Animal Groups and Surgical Procedure
This study was in accordance with the National Institutes of Health guidelines for
the treatment of animals and was approved hy the Institutional Animal Care and Use
Committee at Loma Linda University. Postnatal day-7 Sprague-Dawley rats were
randomly assigned to the following groups: sham, HI [Vehicle], HI + G-CSF daily for 5
days [G-CSF(5d)], or HI + G-CSF daily for 10 days [G-CSF(lOd)]. Hl-groups were
anesthetized with 3% isoflurane and had the right common carotid artery permanently
ligated followed hy 1.5 hours (h) of recovery. Afterwards, pups were placed in a glass jar
(submerged in a water bath maintained at BV^C) perfused with 8% 02/92% N2 for 2 h.
Sham rats had the common carotid artery exposed, hut not ligated. All rats were
sacrificed 5 w after HI surgery under general anesthesia [ketamine (80mg/kg)/xylazine
(lOmg/kg)] by decapitation.
Treatment Method
Some pups were treated suhcutaneously with G-CSF (Amgen Inc., Thousand
Oaks, CA) at 50pg/kg dosage diluted in saline. Treatment was injected at 1 h after
hj'poxia followed hy an additional one injection per day for 5 days (6 total injections) or
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for 10 days (11 total injections). Vehicle pups received subcutaneous injections of saline
following the same regimen.
Evaluation of Brain Damage and Systemic Organ Weight
The HI animal model results in brain damage exclusive to the ipsilateral side [18,
19]; commonly assessed by hemispheric brain weight loss which is highly correlated to
histological loss of brain tissue [20,21]. Brain tissue (sham = 5; vehicle =13; G-CSF
(5d) = 12; G-CSF (lOd) = 13) was removed and the hemispheres were separated by a
midline incision and weighed on a high-precision balance (sensitivity ± 0.001 g). Data
was expressed as a ratio of ipsilateral (right) to contralateral (left) hemispheric weights.
The heart, spleen, and liver were also isolated and weighed. Data for systemic organs was
expressed as a ratio of organ weight to body weight.
Assessment of Neurobehavioral Deficits
The behavior of the rats was blindly evaluated using 8 sensorimotor (postural
reflex, back pressure, lateral pressure, proprioceptive limb placing, lateral placement,
forelimb placement, foot-fault, and rotarod) tests [2,20]; and a test (T-maze) to ascertain
short-term or working memory, as well as complex cortical fimction [22,23].
Methodology was as previously described for the first 6 sensorimotor tests [2] and scored
accordingly: 0 for immediate and correct placement; 1 for delayed and/or incomplete
placement; 2 for no placement. Scores corresponded to raw values: 0 score =100; 1 score
= 50; 2 score = 0. In the foot-fault test, the rat was placed on a horizontal grid floor (36 x
13 in, square size 3x3 cm, wire diameter 0.4 cm) for a duration of 2 min. A foot-fault
was noted when a paw fell throtigh an opening in the grid floor. In the rotarod test, rats
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were placed on a rotating treadmill (diameter 14 cm) initially at rest (stationary) for a
maximum of 1 min. In the second round of testing, the treadmill was set in motion at a
constant speed of 5 rotations per minute (rpm) for a maximum of 1 min. Finally in the
third round of testing, the treadmill was set in motion at an accelerated speed of 5-40 rpm
for a maximum of 2 min. Each animal had 2 trials/round of testing. The time spent by the
animal on the rotarod during each round was noted. In the T-maze test, rats were placed
at the base of the T-maze (stem 40 x 10 cm, arm 46 x 10 cm) and allowed to explore until
an arm of the maze was chosen. Each animal was given 10 trials and the sequence of
right and left arm choices were expressed as the percent of spontaneous alternation.
Data Analysis
Data was expressed as mean i SEM. Using a commercially available software
(Sigma Stat 3.0.1, Aspire Software, Ashbum, VA), one-way ANOVA and Tukey test
were implemented to determine significance in differences between groups. Kruskal-
Wallis ANOVA followed by Dunn's test was used for neurobehavioral analysis.
Significance was accepted at p < 0.05.
Results
G-CSF Promotes Physical Development
Hl-induced somatic growth retardation starting from 1 d after insult is a common
finding in animal experiments [3,24]. Representative pictures demonstrate the significant
differences in physical development between rats injected with vehicle or G-CSF, at the
completion of 5 day dosing regimen or 10 day dosing regimen (Figure 36). Vehicle rats
gained significantly less weight than sham after 1 w following HI (7.73 ± 0.42 vs. 13.38
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± 0.42; Figure 37); an effect attenuated by both G-CSF treatment regimens (5d: 10.71 ±
0.53; lOd: 10.49 ± 0.62). After 3 w following HI, G-CSF(5d) continued to improve
V
weight gain as compared to vehicle (66.54 ± 1.85 vs. 58.87 ± 1.89). Vehicle pups
however did catch up in weight since the amount of weight gained over the entirety of the
study was not significantly less than that of sham rats (125.01 ± 3.30 vs. 136.12 ± 7.40).
On the other hand, rats treated with 5 days of G-CSF (143.39 ± 3.58) gained significantly
more weight over 5 w as compared to vehicle rats, but did not differ from those treated
for 10 days with G-CSF (136.09 ± 4.60).
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Figure 36. Photographs of Physical Appearance of Pups at the Completion of Treatment.
There are marked differences in physical development at the completion of 5 d of G-CSF






























Figure 37. Effect of G-CSF Treatment on Weekly Mean Body Weight Gain. Vehicle rats
gained significantly less weight at 1 week and 3 weeks post-HI, but appeared to catch up
to weight of sham rats after 5 weeks. Both treatment regimens improved weight gain at
the 1 week time point; however the G-CSF(5d) rats gained an average weight
significantly greater than vehicle rats at all tested intervals. Data represent mean ± SEM;
*p < 0.05 versus sham, #p < 0.05 versus vehicle.
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G-CSF Maintains Brain and Systemic Organ Weight
Neonatal encephalopathy involves multiple organs and not just the brain [25,26];
therefore, effects of treatment interventions should be explored across multiple organ
systems [27]. Hl-injury resulted in significant brain atrophy of the lesioned hemisphere
(19.60 ± 3.09%); remarkably, treatment with G-CSF (5d: 8.70 ± 2.18%; lOd: 9.70 ±
2.39%) demonstrated less damage to the brain tissue 5 w post-insult (Figure 38).
Although vehicle rats appeared to have a smaller heart compared to sham, statistical
significance was not reached (Figure 39). When compared to G-CSF(5d)-treated rats,
vehicle rats had a 16.11% reduction in heart to body ratio. Although G-CSF(5d)
treatment appeared to additionally improve spleen and liver weights, no statistical
V
differences were detected between groups.
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Figure 38. Brain Atrophy 5-Weeks After HI Insult. Significant loss of right-to-left
hemispheric (RH:LH) weight ratio is evident in vehicle rats and improved by G-CSF(5d)
and G-CSF(lOd). Data represent mean ± SEM; *p < 0.05 versus sham, #p < 0.05 versus
vehicle.
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Figure 39. Heart, Spleen, and Liver Weights 5-Weeks After HI Insult. G-CSF(5d)
significantly improved heart-to-body weight ratio as compared to vehicle. Representative
pictures of organs. Data represent mean ± SEM; #p < 0.05 versus vehicle.
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G-CSF Ameliorates Hl-Induced Functional Deficits
In all behavior tests, vehicle rats performed significantly worse than sham. This
showed consistency in inducing severe damage across all tested brain regions. Numbers
in parenthesis represent mean raw score. In the postural reflex test, the contralateral
forelimb of the vehicle rats was completely flexed (16.67 ± 6.29); while treatment with
G-CSF(5d) and G-CSF(lOd) significantly improved this deficit (5d: 72.22 ± 8.78; lOd:
66.67 ± 8.33; Figure 40). In the remaining 5 placement tests, the vehicle rats averaged a
raw score ranging from 20.00 ± 6.55 to 43.33 ± 4.54; this meant vehicle rats were
consistently unresponsive in these tasks. Although the G-CSF(1 Od) significantly
improved these deficits across tasks, G-CSF(5d) did so in all but the proprioceptive limb
placing test. Rats subjected to HI displayed significantly reduced sensorimotor
)
coordination as assessed using the foot-fault test compared to sham (34.20 ± 2.27 vs. 12.4
± 1.57). Both G-CSF treatment for 5 d (21.11 ± 1.76) and 10 d (17.56 ± 0.99)
significantly attenuated the Hl-induced deficits. Vehicle rats also displayed a significant
reduction in muscle strength and motor coordination compared to sham (32.57 ± 3.45 vs.
50.24 ± 2.54), as assessed by the rotarod test. Treatment with G-CSF (5d: 50.49 ± 2.94;
lOd: 58.02 ± 1.04) improved the latency to fall period when the treadmill was stationary.
When set at constant velocity, G-CSF (5d: 54.39 ± 2.38; lOd: 59.49 ± 0.51) significantly
I
improved the Hl-induced (40.57 ±4.14) deficits. During acceleration of the treadmill,
animals fi-om both G-CSF regimens (5d: 56.81 ±4.10; lOd: 65.83 ± 4.11) again
performed significantly better than vehicle (32.44 ± 2.46). In the T-maze, vehicle rats
demonstrated a significant reduction in exploratory behavior and short-term memory as
compared to sham (33.33% ± 3.07 vs. 73.33% ± 2.72). These deficits were significantly
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improved by both G-CSF regimens (5d: 56.79% ± 4.32; lOd: 61.73% ± 1.95); however,








































































































































































































































































Figure 40. Functional Outcome at 5-Weeks After HI Insult. Sensorimotor tests: 100 for
immediate and correct placement; 50 for delayed and/or incomplete placement; 0 for no
placement. Vehicle rats did significantly worse than sham in all tests: postural reflex,
back pressure, lateral pressure, proprioceptive limb placing (P. limb placing), lateral
placement, and forelimb placement. G-CSF(5d) improved deficits in all but those
associated with the P. limb placing test; while G-CSF(lOd) corrected all tested deficits.
Vehicle rats had a greater number of foot-faults during the 2 min testing interval; while,
both treatment regimens attenuated these deficits. In the Rotarod test, vehicle rats
performed significantly worse under all testing conditions: stationary, constant velocity
(5 rpm) and accelerating (5-40 rpm). In the T-Maze test, vehicle and G-CSF(5d) rats
alternated significantly less between the two arms of the maze as compared to sham;
however, G-CSF(5d) and G-CSF (lOd) performed significantly better at this task than
vehicle. Data represent mean ± SEM; *p < .05 versus sham, #p < .05 versus vehicle.
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Discussion
This study demonstrates the long-term efficacy of G-CSF administration on
behavioral and neuropathological recovery in an established rat model of neonatal HI
injxuy. To our knowledge, our data is the first to demonstrate the effect of multiple
treatments of G-CSF on Hl-induced sensorimotor and memory impairment. The
importance of the present findings may be highlighted by: 1) the elucidation of a
beneficial treatment regimen with long-term, brain and system organ protection; 2) the
significant improvement in neurological function across a battery of tests, which renders
these results important for the treatment of neonatal encephalopathy in the clinical
setting.
Experimental stroke studies have found treatment with G-CSF to be well tolerated
without major side effects [28]; of which, may include, mild to moderate hone and/or
musculoskeletal pain, anemia, thrombocytopenia, and injection site reactions [29].
Nevertheless, the safety profile of G-CSF appears to be fairly innocuous, even after years
of administration to patients with severe neutropenia [29]. In experimental neonatal HI, a
single dose of G-CSF immediately after hypoxia is neuroprotective 2 w following insult
[17]; while multiple doses confer morphological benefits up to 3 w [6]. Based on these
findings, evidence that neuronal damage likely develops over a period of time [30], and
that neuroreparative processes may need stimulation after 24 h when the inflammatory
responses have declined [31], we chose to administer multiple doses of G-CSF over 5
days or 10 days following HI. The efficacy of the treatment regimen was determined by
its ability to improve physical development, protect brain tissue, and improve long-term
functional outcome.
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Fetal growth retardation is a Hl-related outcome, and can be used as an indicator
of general well-being [17]. From the body weight data, it is evident that G-CSF treatment
significantly improves physical development during the critical period following brain
injury. Whilst both treatment protocols initially promoted weight gain after HI, the rats
treated with G-CSF(5d) gained significantly more weight at the end of 5 w compared to
their vehicle-administered counterpart. Moreover, previous studies have shown that low
body weight is accompanied by a decreased heart weight [32] - an effect we found to be
counteracted by G-CSF(5d). An explanation has been that slow growing pups have a
significantly lower number of cardiomyocytes, as well as qualitative changes of the
subcellular structures [32]. Other systemic organs affected by fetal growth retardation are
the spleen and liver; possibly due to oxygen deprivation and inadequate macro- and
micronutrients during fetal life resulting fi*om the preferential blood flow to vital organs
such as the brain and heart [33]. However, our results show that these acute affects do not
have long-term implications, and that the neonatal rat compensates as there were no
differences found between groups when comparing spleen and liver weights.
Although no significant differences were found between groups, the G-CSF(5d)
treated animals appeared to have a larger body, heart, spleen, and liver weights compared
to those in the sham group. This finding may spark concern about unintentional organ
hypertrophy upon prolonged treatment with growth factors. In fact, spleen enlargements
have been reported during repetitive G-CSF administration - a likely result of G-CSF-
induced extramedullary hematopoiesis [34]. However, the observed trend toward organ
hypertrophy in the 5 day treated group may be entirely incidental since more prolonged
treatment (i.e, 10 day) did not demonstrate the same trend. Aside fi-om promoting weight
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gain, G-CSF treatment also protected brain integrity in the neonate. Both G-CSF(5d) and
G-CSF(lOd) prevented the long-term loss of brain tissue. The anti-apoptotic [6], anti-
inflammatory [35], and excitoprotective [36] properties of G-CSF maybe responsible for
the long-term attenuation in brain damage; however the exact mechanism is yet unclear.
Preservation of structural integrity by G-CSF treatment resulted in improved
motor performance. Brain regions, such as the sensorimotor cortex and hippocampus, are
critical for the maintenance of sensorimotor function and are adversely affected by HI
insult [37]. Accordingly, damage to these vulnerable brain regions severely affected
functional performance of vehicle rats. Conversely, G-CSF-induced morphological
protection manifested into muscle strength, motor coordination, reflexes, limb placing,
short-term memory, and exploratory behavior similar to that of control animals. The
recovery processes that are activated and/or amplified by G-CSF, and thereby exert
beneficial effects on post-HI recovery are yet to be elucidated.
G-CSF is an attractive candidate as a therapeutic modality for the human neonate,
and may be expanded as treatment to other clinical fields that share common
pathophysiological features, such as neonatal stroke, global cerebral ischemia, and
neonatal hemorrhagic brain injury. In the clinical setting, G-CSF has been administered
to neutropenic neonates with sepsis once daily for 3-5 days. Based on this, and the
positive results we obtained fi-om 5 day treatment with G-CSF, the most relevant time
period of treatment in the human might be a 5 day dosing regimen. Our experimental
study (i.e, use of a clinically-relevant animal model, multiple treatment regimens, and
neurobehavioral assessment) provides a foundation for exploring clinical translation.
However, we anticipate the need for a dose response study, as well as a more
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comprehensive evaluation of safety [38] before moving G-CSF to the clinical setting as
treatment against neonatal hypoxic-ischemic brain damage.
Overall, the findings from the present study provide new insight to the therapeutic
repertoire of G-CSF. Specifically, that treatment with G-CSF attenuates long-term brain
I
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Discussion
The data presented here suggests targeting of key components of the
neuroinflammatory response confers neuroprotection after a hypoxic-ischemic insult.
Specifically, we found: 1) Inhibition of COX-2 attenuates the Hl-induced consequences
by reducing brain damage, and improving long-term functional deficits, and somatic and
systemic organ growth; 2) Splenic immune cells to be the major source of COX-2 in the
ischemic brain; and that COX-2 modulates downstream targets of neuroinflammation and
cell death in astrocjlies and neurons, respectively; 3) Short-term administration of the
neurotrophic factor, G-CSF, improves long-term behavioral and neuropathological
recovery after a hypoxic-ischemic insult.
Neuroprotective Effects of COX-2 Inhibition
To replicate the clinical features seen in human infants after asphyxia, we used a
well-established rodent model that combines unilateral carotid artery ligation with
exposure to 2 hours of hypoxia (1). This model has been very informative for
understanding the underlying mechanisms of brain injury from peri-natal hypoxia, and
for the testing of potential neuroprotective agents (2). A hypoxic-ischemic insult is
associated with increased mortality and somatic growth retardation in both patients and
experimental studies (3,4,5). In accordance to these findings, we found a higher incidence
of mortality and lower body weight in HI injured rats. In contrast, 100% of animals that
were treated with a COX-2 inhibitor survived the injury and were able to maintain their
body weights to that of control animals. Aside from these Hl-induced consequences,
interruption of placental blood flow can affect cerebral and systemic function (6,7);
therefore, potential treatment modalities should address not only cerebral protection but
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rather involve multiple organ systems. As such, we foimd that animals that had
experienced a HI insult had significant brain and systemic organ tissue loss compared to
that of control. This effect was counteracted when animals were treated with a COX-
inhibitor. Moreover, attenuation of brain atrophy by blockade of COX-2 appeared to also
result in improved motor, cognitive, and behavioral function 6 weeks after HI injury. This
long-term assessment of treated animals was a particularly important finding considering
past therapeutic modalities in neonatology have resulted in unforeseen side-effects (8,9).
These results suggest that inhibition of COX-2 may provide major benefits for brain and
systemic orgau integrity, neurobehavioral deficits, and survival after neonatal HI.
Collectively, these data provide a foundation for an investigation of COX-2-dependent
mechanisms in neonatal hypoxic-ischemic brain injury.
COX-2-Dependent Mechanisms in Brain-Immune Interactions
Having established that COX-2 is a mediator of brain damage after a hypoxic-
ischemie event, we sought to determine whether it plays a role in brain-immune cell
interactions. First, to elucidate the possible impact of the systemic inflammatory response
on astroglia-neuron signaling, we removed the spleen, the largest pool of peripheral
immune cells prior to HI and studied the short- and long-term outcomes in the neonate.
Next, we sought to determine whether COX-2 mediates the mechanism by which
activated immune cells induce pro-inflammatory cjdokine production by astrocytes (16).
This is especially important since recent data suggests that enhanced interleukin-15 (IL-
15) expression in astrocytes is a major propagator of inflammatory responses after central
nervous system injury (17). In addition, the degree of involvement from the innate
immune system has been shown to correlate with the extent of neuronal damage in the
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post-ischemic tissue (18). Moreover, studies suggest dysfunction of the phosphoinositide-
3-kinase (PI3K)/Akt survival pathway to be responsible for triggering apoptotic cascades
in the brain (19). However, it was still unknown whether down-regulation of the PI3K
pathway and subsequent neuronal death in Hl-injured rats occurs in response to COX-2
from infiltrating immune cells. Therefore, we used a gain and loss of function approach
(pharmacological activation or inhibition, respectively) for COX-2, a neutralizing
antibody for IL-15, and a gene silencer for natural killer (NK) cells in both
splenectomized and non-splenectomized rats to verify the role of COX-2 in splenic
immune cell responses following HI.
Our major new finding was that spleen-derived immune cells serve as a major
source of COX-2 in the ischemic brain, and are principal mediators of infarct growth,
long-term brain atrophy, somatic restriction, and functional deterioration following
neonatal HI. More specifically, we found that the influx of COX-2 expressing immune
cells enhances astrocytic IL-15 production and caspase-3-mediated neuronal death, which
in sum propagates brain damage. In line with other studies, our data confirms that the
secondary brain injury in the Hl-induced neonate includes apoptosis (20) and activation
of local inflammation (21) both of which may be triggered by spleen-derived immune
cells. We believe that the findings of this study provide mechanistic basis for potential
novel modalities ameliorating long-term outcomes of neonatal hypoxia-ischemia.
Long-Term Behavioral and Morphological Effects of G-CSF Treatment
Excessive and/or prolonged activation of inflammatory mediators can decrease
neurotrophic support and neurogenesis in brain areas responsible for behavior and
cognition (10,11). For example, LPS-induced cognitive impairment and elevated levels of
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TNFa and IL-1 are associated with decreased hippocampal expression of brain-derived
neurotrophic factor and reduced neurogenesis (12). Blockade of IL-1 receptor, the use of
IL-1 receptor knock-out mice, or transplantation of IL-1 receptor antagonist secreting
neural precursor cells can prevent the effects on behavior, cognition, neurotrophic factors,
and neurogenesis (10,11,13). In line with these findings, studies have shown that
selective inhibition of GOX-2 can increase G-CSF production (14,15), therefore, we
sought to determine the direct effect of G-CSF administration on Hl-induced long-term
behavioral and neuropathological outcome. We found that animals that had experienced a
hypoxic-ischemic insult had severe brain atrophy. Additionally, these animals
demonstrated reflexes, limb placing, muscle strength, motor coordination, short-term
memory, and exploratory behavior that were significantly worse than control animals. In
contrast, Hl-injured animals that were treated with G-CSF showed less brain tissue loss
and scored similarly to the control animals; thereby, implicating the neurotrophic
capabilities of G-CSF to be responsible for the structural preservation and improved
fimctional outcome.
Summary
In summary, the emerging landscape of neuroinflammation reveals highly
complex interactions involving neurons, glia, and peripheral immxme cells in the neonatal
brain injured by HI. The mechanism of these multidirectional communications and their
specific involvement in brain injury began to unveil only recently. It is however
important to further dissect molecular orchestrators of these interaction in order to devise
novel therapeutics with increased likelihood of success in clinical trials. Recent studies
demonstrated a critical involvement of COX-2 in brain inflammation after HI and implied
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the use of COX inhibitors in treatment for neonatal encephalopathy in the clinical setting.
While COX-2 appears as a major neuroinflammatory mediator after HI, G-CSF can
negatively modulate inflammatory responses in the immature brain. Interestingly, COX-2
can also mitigate G-CSF action and thereby can compromise neuronal survivability in the
brain. Collectively, these finding suggest that COX-2 inhibitors and exogenous G-CSF
are promising treatment modalities on which to rely.
Perspective
Based on the results obtained so far it is also reasonable to anticipate that COX-2
plays a major role in mediating neuro-glial interactions as well as in orchestrating
immunological cell response in Hl-induced brain injury. Further studies of this matter are
warranted.
In the adult stroke model, splenectomy prior to cerebral ischemia reduced brain
injury by elimination of the largest pool of immunological cells in the system.
Consequently, it positively verified the involvement of peripheral immune cells in the
mechanism of brain injury progression after stroke. Considering that all clinical trials
with anti-flammatory agents against stroke failed, these latest findings may point towards
the reassessment as to whether anti-inflanimatory therapies for stroke can reduce the
peripheral immune system's involvement. These new evaluation criteria would also stand
true for numerous candidate treatments of neonatal HI currently tested in neuroscience
labs, including G-CSF. In addition, it would be worthwhile to develop
immunomodulatory therapies aimed at switching immune response after HI to Thi cells.
A significant progress in this field should not come as a surprise quite soon considering
latest studies employing "beneficial" subtypes of T cells (Th2 /Ths) to support
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neuroprotection and/or regeneration. However, the existing studies of neuro-glial-
immune interactions have been conducted almost exclusively in adult stroke models. In
addition, few relevant studies of neonatal HI included unsexed animals. Thus the
peripheral immune involvement in neonatal HI awaits further investigations, considering
distinct characteristics of the developing brain and immunologic immaturity of the
neonate. In conclusion, there is a need to decipher molecular circuitry of neuro-glial-
immune communications in the hypoxic-ischemic neonatal brain with gender specific
investigations. It is believed that targeting master mediators of these interactions may
pave the way to the first successful clinical trial with therapeutic agents that combat
neuroinfiammation after neonatal HI.
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